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ABSTRACT 
VGF (non-acronymic), a neuropeptide precursor protein related to the chromogranin 
family, has been implicated in neuroplasticity associated with depression, learning and 
memory, and chronic pain. The Vulchanova lab has previously demonstrated that the 
VGF-derived peptide TLQP-21 contributes to both the development and maintenance of 
hypersensitivity after peripheral nerve injury and inflammation. The receptor for TLQP-21 
is the complement-3a receptor C3aR1. Although the complement system has been 
implicated in mechanisms of neuropathic pain, the potential relevance of C3aR1 in these 
processes has not been addressed.  This thesis examines the involvement of C3aR1 
signaling following spared nerve injury (SNI) and spinal cord injury (SCI). I hypothesized 
that C3aR1 located on microglia are a key signaling mediator in neuropathic pain following 
peripheral and central injury.  In this thesis, I show that C3aR1 is localized to microglia in 
both naïve mice, and mice following SNI and SCI.  Following SNI, an antagonist to C3aR1 
was able to transiently attenuate mechanical hypersensitivity. Additionally, I found that 
TLQP-21 specifically activates C3aR1 located on microglia. I identified that there was 
upregulation of C3aR1 in a time-dependent manner following SNI and SCI. The early 
increase of receptor expression indicates a potentially important role of C3aR1 signaling 
throughout the acute stages of peripheral and central nervous system injury. Prior to this 
thesis work, there were limited studies examining sensory changes occurring in male mice 
following SCI. I provide the most thorough characterization of behavior following SCI in 
male mice to date, and show for the first time that SCI mice exhibit a dramatic loss of light 
touch sensitivity. Utilizing an antisense oligonucleotide, I show a potentially protective 
effect of knocking down the C3aR1 receptor during the acute phase of spinal cord injury. 
I found that knockdown attenuated the loss of light touch sensitivity seen in spinal cord 
injury animals. Overall, this thesis highlights the potential relevance of            iv.             
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C3aR1 as a therapeutic target following injury, and uncovers the complex role complement 
receptor-mediated immune signaling has in neuropathic pain.  
 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v. 
8	
TABLE OF CONTENTS 
List of Tables  vii. 
List of Figures vii - viii. 
Introduction Pg. 1-12 
Chapter 1 – Expression and function of the Complement-3a receptor 
following peripheral nerve injury  Pg. 12 - 33 
Chapter 2 – Comprehensive characterization of sensory behavior 
following a mouse model of spinal cord injury Pg. 34 - 65 
Chapter 3 – Antisense oligonucleotide-mediated knockdown of Complement-3a 
receptor: Effect on peripheral and central models of neuropathic pain Pg. 66 - 102 
Discussion Pg. 103 - 109 
References Pg. 110 - 122 
vi.
	 9	
Tables 
Table 2.1: Experimental groups in chapter 2      37 
Table 2.2: BMS Scores        42 
Table 3.1: Experimental groups in chapter 3      70 
Figures 
Figure 1.1: Spinal localization of C3aR1.      20 
Figure 1.2: TLQP-21 activates C3aR1 in cultured primary microglia.  23 
Figure 1.3:  C3aR1 mediates peripheral nerve injury-induced hypersensitivity. 25 
Figure 1.4: Spinal expression of C3aR1 increases after nerve injury.  27 
Figure 1.5: Spinal C3aR1-ir is localized in microglia after nerve injury.  29 
Figure 2.1: Male ICR mice recover locomotion following mild and  
moderate thoracic contusion spinal cord injury in a reproducible manner  43 
Figure 2.2: Analysis of mild 50 kdyn thoracic contusion spinal cord injury 
 effects on fine motor coordination in male ICR mice    45 
Figure 2.3: Mechanical withdrawal thresholds are not altered following mild and 
moderate thoracic contusion spinal cord injury in male ICR mice   48 
Figure 2.4: Following mild or moderate thoracic contusion spinal cord injury,  51 
injury severity measured on day one affects whether male ICR mice develop  
heat hyperalgesia 
Figure 2.5: Following mild or moderate thoracic contusion spinal cord injury, 
 injury severity measured on day one affects how much male ICR mice burrow 54 
Figure 2.6: Mild and moderate thoracic contusion spinal cord injury induces 
 a dramatic loss of light touch sensitivity in male ICR mice    57 
  
 vii. 
	 10	
Figure 3.1: Treatment with C3aR1 ASO significantly knocks down expression  
of C3aR1 in the spinal cord.        74  
Fig. 3.2: Treatment with C3aR1 ASO has no effect on the development or  
maintenance of hypersensitivity following peripheral nerve injury   76 
Figure 3.3: Spinal expression of C3aR1 and Iba1 is increased 6 days after  
spinal cord injury.         78 
Figure 3.4: Iba1 and C3aR1 are present in the dorsal columns of SCI mice. 79 
Figure 3.5: Treatment with C3aR1 ASO 3 days following a mild 50 kdyn  
contusion SCI has variable effect on pain-related behaviors.   84 
Figure 3.6: Treatment with C3aR1 ASO 3 days following moderate 75 kdyn  
thoracic contusion SCI has a variable effect on behavior in male ICR mice  88 
Figure 3.7: Control ASO induces thermal hypersensitivity in injured subjects. 91 
Figure 3.8: Control ASO-induced changes in expression of C3aR1 in injured   94      
subjects 	
 
 
 
 
 
 
 
 
 
 
 
 
viii
	 1	
 
INTRODUCTION 
 
Chronic pain overview 
Pain is defined as “an unpleasant sensory or emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage” (International 
Association for the Study of Pain, 2017). Chronic pain affects approximately 20 percent of 
the worldwide population, or around 1.5 billion people. Chronic pain is one of the leading 
causes of disability (Nahin, 2015). Over 100 million people in the United States suffer from 
chronic pain (Johannes, Le, Zhou, Johnston, & Dwor kin, 2010; Nahin, 2015), with 
economic costs equaling 600 billion dollars per year in treatment and lost productivity 
(Gaskin & Richard, 2012). Chronic pain was added to the most recent International 
Classification of Diseases (ICD-11) released in May 2019, where it was defined as “pain 
that lasts or recurs for more than three months” (Benoliel et al., 2019; Treede et al., 2015). 
 
Why and how do we have pain?  
Pain is an important protective mechanism, alerting us to potential bodily damage in 
addition to encouraging us to guard injured areas from further damage. Pain information 
is sent by primary afferents called nociceptors. Nociceptors fall into two major classes, 
including thinly myelinated a-delta fibers and small diameter unmyelinated c-fibers (Dubin 
& Patapoutian, 2010). The types of stimuli that nociceptors respond to include 
temperature, mechanical stimuli, and chemical stimuli. Nociceptors respond within a 
narrow physical range. The specific stimuli nociceptors are activated by depend on the 
receptors expressed at the peripheral terminals. Nociceptors innervated by a-delta fibers 
produce short latency pain that is described as sharp or pricking, whereas C-fibers 
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produce dull, burning pain that is diffusely localized and poorly tolerated (Ringkamp & 
Meyer, 2010).  
Chronic Pain: Peripheral and Central Sensitization  
Chronic pain can occur due to maladaptive changes transpiring at both the peripheral and 
central levels. Peripheral sensitization occurs at the level of the nociceptors, at the 
terminals located in the target organs that have undergone injury. Sensitization of the 
nociceptive afferents leads to lowered thresholds. These thresholds are lowered in 
response to the release of various chemicals generated during tissue injury and 
inflammation (Stein et al., 2009). Immune cells in the periphery can release some of these 
factors, including cytokines, prostaglandins, chemokines, and growth factors (Ren & 
Dubner, 2010). Other chemicals, such as ATP and glutamate, are released from the 
damaged cells at the location of the injury (Millan, 1999).  
 
Central sensitization occurs at the level of the spinal cord, through a phenomenon called 
Wind Up. Dorsal horn neurons can present with enhanced excitability due to sustained C-
fiber firing. The consistent action potentials lead to post-synaptic depolarization which 
activates NMDA receptors. This causes long-term changes in cellular excitability, referred 
to as spinal long term potentiation (LTP), and this can lead to spontaneous firing of dorsal 
horn neurons (D’Mello & Dickenson, 2008; Ji, Kohno, Moore, & Woolf, 2003). Another 
mechanism leading to central sensitization is a reduction of inhibitory drive. The majority 
of neurons in the spinal cord dorsal horn are interneurons, with a number of these being 
inhibitory (Peirs & Seal, 2016). Inhibitory neurons play and important role in the “gate 
theory” of pain, developed by Melzak and Wall in the 1960s (Melzack & Wall, 1965). The 
way that the central nervous system normally controls the perception of pain is through 
local circuits in the spinal cord dorsal horn, necessary to balance incoming nociceptive 
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and non-nociceptive input. There is a convergence of these two in the dorsal horn, coming 
from nociceptive C-fibers and non-nociceptive a-beta fibers. Activation of non-nociceptive 
fibers inhibits the transmission of nociceptive input to the brain, but a delicate balance of 
the system is necessary. During central sensitization, there is an increase of intracellular 
chloride that occurs as a result of downregulation of potassium-chloride co-transporters. 
This can lead to reduced inhibitory (GABAergic and glycinergic) transmission, known as 
disinhibition, or even a reversal of inhibitory activity to excitatory (Meisner, Marsh, & 
Marsh, 2010a; Price, Cervero, & de Koninck, 2005; Price & Prescott, 2015; Zeilhofer, 
Benke, & Yevenes, 2011).  
 
Central sensitization occurring in the spinal cord leads to two behavioral phenomena 
known as allodynia and hyperalgesia. Allodynia is when a stimulus that is normally not 
painful, such as a normal touch, is perceived as painful. Hyperalgesia is when a normally 
painful stimulus elicits an enhanced painful sensation. These two behavioral 
consequences in particular are hallmarks of neuropathic pain                                                    
(Eide, Jørum, & Stenehjem, 1996; Jensen & Finnerup, 2014).  
 
Chronic Pain: Immune System Involvement 
The immune system’s role in chronic pain has been investigated with great interest over 
the past few decades. Historically, many believed the immune system only played a role 
in pain arising from inflammation. It has become clear that immune cells are involved at 
both the peripheral and central levels. 
 
	 4	
 In the periphery, when there is disruption of a barrier, such as the skin, the immune 
system responds in a stereotypical fashion. Almost immediately following this injury, the 
cell intrinsic and innate immune system is activated, as a fast and nonspecific response 
(Kupper & Fuhlbrigge, 2004; Uematsu & Akira, 2008). Cell types involved in the immediate 
response include complement factors, macrophages, dendritic cells, eosinophils, mast 
cells, and neutrophils, among others. Around 96 hours after injury, the adaptive immune 
system is activated, with specific responses that carry a “memory.” Cell types include 
CD4+ and CD8+ T-cells, and B-cells that secrete antibodies (Bangert, Brunner, & Stingl, 
2011; Grice & Segre, 2011). The infiltration of immune cells to the injured barrier are 
capable of producing inflammatory pain, through the release of DAMPs, or danger 
associated molecular patterns, aka alarmins (Schaefer, 2014). These can include 
proinflammatory cytokines such as TNF-alpha and IL-1-beta released by macrophages, 
CGRP and Substance P released by neurons, or prostaglandins released by mast cells. 
The influx of inflammatory agents can cause localized swelling, redness, and pain due to 
activation of nociceptors (Schaefer, 2014; Tang, Kang, Coyne, Zeh, & Lotze, 2012).  
 
In addition to immune activation occurring at the level of the skin, when there are injuries 
to peripheral nerves, the immune system is a key component of the development of 
neuropathic pain. Macrophages can respond to chemotactic signals and are recruited to 
the peripheral nerves and the dorsal root ganglion following injury (Cui, Holmin, 
Mathiesen, Meyerson, & Linderoth, 2000; T. Liu, Van Rooijen, & Tracey, 2000). Activated 
macrophages release a number of proinflammatory cytokines capable of binding to 
cytokine receptors located on peripheral nerves, thus activating them. Interestingly, in 
addition to the pronociceptive actions of immune cells at the site of peripheral nerve injury, 
there are also potentially protective roles that can occur in the right conditions. Following 
	 5	
peripheral nerve injury, opioid receptors are upregulated at the site of injury, and activation 
of leukocytes can induce endogenous opioid release (Sauer et al., 2014). Additionally, 
macrophages in the M2 (anti-inflammatory) state can also release endogenous opioids to 
reduce pain-related behavior following peripheral nerve injury (Pannell et al., 2016). 
 
The immune system also plays a critical role in pain at the level of the central nervous 
system. The resident immune cells in the central nervous system are microglia, which 
have a monocytic origin, similar to macrophages. Microglia therefore overlap significantly 
with macrophages in terms of their receptors and factors that they produce (Kreutzberg, 
1996; Ransohoff & Brown, 2012). Microglia make up approximately 10 to 15 percent of all 
cells in the central nervous system. As the resident immune cells, microglia are continually 
sampling their environment for potential damage. The role of microglia in a healthy central 
nervous system is to scan for damaged neurons, unnecessary synapses, and infectious 
agents (Kreutzberg, 1996). They phagocytose damaged tissue, and are responsible for 
performing as antigen-presenting cells to activate T-cells (Gehrmann, Matsumoto, & 
Kreutzberg, 1995). Due to the sensitivity of neurons to damage, microglia are sensitive to 
the slightest change in environmental milieu. Microglial activation is a crucial component 
of central sensitization and neuropathic pain. In the spinal dorsal horn, microglia surround 
the spinal terminals of nociceptors. Following peripheral injury, nociceptors are activated, 
flooding the dorsal horn with pronociceptive peptides such as CGRP and Substance P, in 
addition to excitatory neurotransmitters such as glutamate (Reichling & Levine, 2009). 
Microglia express a number of neurotransmitter receptors and become activated by these 
factors released at the terminals (H. Liu, Leak, & Hu, 2016). Activated microglia then 
release a number of proinflammatory factors such as TNF-alpha, IL-1beta, ATP, and 
prostaglandins (Austin & Moalem-Taylor, 2010). These factors are then capable of binding 
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to receptors located on both the primary afferent terminal and the second order neuron. 
This soup of proinflammatory factors entering the environmental milieu simultaneously 
can induce and/or prolong central sensitization.  Many mouse and rat studies have 
blocked the activation of microglia following peripheral and central injury and have been 
able to attenuate the development of neuropathic pain (Hains, 2006b; Sorge et al., 2011; 
Staniland et al., 2010; Zhuang et al., 2007).  
 
Neuropathic Pain: Animal Models 
There are over forty existing animal models utilized for the study of neuropathic pain that 
are produced from peripheral or central nervous system injury (Jaggi, Jain, & Singh, 2011). 
The studies presented in this thesis use a peripheral model, spared nerve injury (SNI), 
and a central model, spinal cord injury (SCI). 
 
The spared nerve injury (SNI) model is a well-established model of peripheral nerve injury 
that produces substantial and prolonged changes in mechanical sensitivity and cold 
responsiveness that closely mimic the cutaneous hypersensitivity associated with clinical 
neuropathic pain (Decosterd & Woolf, 2000). In this injury, the three branches of the sciatic 
nerve are exposed, between the hip and the knee. The peroneal and tibial nerves are 
ligated and cut, and the sural nerve is left intact. Following this injury, subjects develop 
mechanical hypersensitivity in the ipsilateral hindpaw, in the lateral portion of the hindpaw 
which is innervated by the sural nerve (Decosterd & Woolf, 2000). This hypersensitivity is 
long-lasting, and interventions can be administered to disrupt both the development and 
maintenance of pain behavior following SNI.   
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The spinal cord injury model isn’t necessarily one singular model, but rather a group of 
injuries that can be elicited by impact, transection, or excitotoxic chemicals (Cheriyan et 
al., 2014; Jaggi et al., 2011). The work presented in this thesis used a thoracic contusion 
injury in mice to study pain-related behaviors. The majority of animal studies examining 
pain behavior following spinal cord injury have been done in rats. Following thoracic 
contusion spinal cord injury, rats typically develop mechanical allodynia and thermal 
hyperalgesia (Hains, 2006a; Hama & Sagen, 2007; Peng et al., 2009; Sweitzer, Pahl, & 
DeLeo, 2006; Zhao, Waxman, & Hains, 2007a). Performing SCI in mice is more complex, 
due to their smaller size. Mice develop heat hyperalgesia reliably following SCI, but 
development of mechanical hypersensitivity is more variable (Hoschouer, Basso, & 
Jakeman, 2010; Kerr & David, 2007; Meisner et al., 2010a). 
 
Granins: VGF 
Granins are a family of proteins that are processed into a number of bioactive peptides 
that are packaged into large dense-core vesicles and secreted via the regulated secretory 
pathway. The hallmark of granins compared to other secretory proteins is their size and 
their low isoelectric point. Granins are typically larger than 50 kDa, and have an isoelectric 
point between 4.5 and 6.1, indicating an acidic composition (Alessandro Bartolomucci et 
al., 2011; Helle, 2004; Taupenot, Harper, & O’Connor, 2003). Granins are typically 
expressed in endocrine cells and peptidergic neurons, where they are synthesized in the 
rough endoplasmic reticulum. Proteins that are released via the regulated secretory 
pathway must be initially stimulated by a secretagogue, which binds to the cells that 
produce granins and stimulates the secretion of them. This differs from the constitutive 
secretory pathway, where proteins can be secreted continuously without stimulation. The 
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most well-known proteins in the granin family include chromogranin A and B, 
secretogranin, VGF, and ProSAAS (Alessandro Bartolomucci et al., 2011; Taupenot et al., 
2003).  
 
The neurotrophin-inducible protein VGF (non-acronymic) is 617 amino acids long and is 
expressed in neurons and neuroendocrine cells (Salton, Fischberg, & Dong, 1991). Like 
other granins, it is proteolytically cleaved into a number of bioactive peptides, which are 
packaged into large dense core vesicles and released via the regulated secretory 
pathway. Research on VGF has implicated its involvement in neuroplasticity associated 
with learning and memory, depression, and chronic pain (A. Bartolomucci et al., 2006; 
Hunsberger et al., 2007; Lacroix-Fralish, Austin, Zheng, Levitin, & Mogil, 2011; Lin et al., 
2015; Moss et al., 2008; Riedl et al., 2009; Thakker-Varia et al., 2007)   The Vulchanova 
lab began researching the involvement of VGF in chronic pain following a proteomic 
analysis of dorsal root ganglion (DRG) cultures, a model of axotomized neurons. They 
compared protein levels in cultured DRG at 24 hours utilizing proteomic differential 
expression analysis (Riedl et al., 2009), and found a 45-fold increase in VGF expression, 
more than any other protein analyzed. In addition to DRG cultures, the Vulchanova lab 
examined VGF expression following peripheral nerve injury and inflammation, and found 
rapid and significant increases in expression at multiple timepoints after injury.  
 
The majority of the Vulchanova lab’s work has focused on the C-terminal peptides of VGF. 
There are a number of cleavage sites within the C-terminus of VGF, producing at least 
four known bioactive peptides, TLQP-62, TLQP-21, AQEE-30, and LQEQ-19 (Levi, Ferri, 
Watson, Possenti, & Salton, 2004). These peptides are named for the first four amino 
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acids in the sequence, followed by the length of the peptide. The largest C-terminal 
peptide is TLQP-62, which is further cleaved into TLQP-21 and AQEE-30. Previous work 
from the Vulchanova lab examined the involvement of TLQP-21 in pain following Complete 
Freund’s adjuvant (CFA) induced inflammation and spared nerve injury, a model of long-
lasting neuropathic pain (Fairbanks et al., 2014). It was found that an antibody to TLQP-
21 (anti-TLQP-21) injected before an intraplantar injection of CFA was able to block the 
development of CFA-induced tactile hypersensitivity beginning at 2 hours post-CFA 
injection. Additionally, anti-TLQP-21 injected either before or after spared nerve injury was 
able to disrupt the development and the maintenance of tactile hypersensitivity. These 
results indicated that TLQP-21 signaling is a critical component of the pronociceptive 
cascade occurring following both inflammatory and neuropathic pain models.  
 
 
Schematic representation of the neuropeptide precursor VGF and its C-terminal peptides. 
VGF peptides are named for their first four amino acids and the total length. 
 
 
TLQP-62	
TLQP-21	
sis, relating to the phenotype of VGF-deficient mice (Hahm
et al. 1999). Indeed, we observed that icv administration to
rats of NERP-2, but not NERP-1, enhanced food intake
(Toshinai, et al., unpublished observation). Of note, the ir-
neurons, observed in the ventral tuberomammillary nucleus
that is important for the regulation of arousal as well as in the
LH where orexins are expressed, suggest their potential roles
in the circadian rhythm and arousal.
In the pituitary, the intermediate/posterior lobe contained
25- to 50-fold higher levels of ir-NERP-1 and ir-NERP-2
than the anterior lobe, suggesting their functions in the
hypothalamo-neurohypophysial system; given their ability to
suppress AVP release from SON and PVN (Yamaguchi et al.
2007), NERPs may inhibit its secretion from the posterior
lobe. Immunohistochemically, cells strongly immunostained
with anti-NERPs antibodies were observed in the posterior
lobe, supporting their relevant roles in this system. In the
intermediate lobe, however, only NERP-1 immunoreactivity
was observed (Fig. 2a–d), which was shown to be co-
localized in a-MSH/proopiomelanocortin-producing mela-
notrope cells but not in folliculo-stellate cells (Fig. 2g–l).
Although this difference needs biochemical verification, it is
postulated that NERP-1 is generated preferentially over
NERP-2 and may function as a circulating hormone after
being secreted into the blood stream. In the anterior lobe,
proteolytic processing may be retarded compared with that in
the intermediate/posterior lobe (Fig. 5a), which might be
related to the lack of ir-cells (Fig. 2).
Although less abundant than in the brain and pituitary, ir-
NERPs were present in peripheral tissues. In the GI tract, ir-
cells were detected in the Meissner and Auerbach plexuses
(Fig. 2m–p). This is in agreement with immunoreactivity
reported in the neural plexus of colon with anti-VGF[443–
588] antibody (Ferri et al. 1992). Biochemically, major
molecular forms of NERP-1 and -2 were consistent in the
brain and GI tract (Fig. 3). These results suggest that NERPs
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Fig. 5 Western blot analysis of ir-NERP-2 and ir-VGF-C in rat tis-
sues. (a, b) Rat tissue extracts immunoprecipitated with anti-NERP-2
or anti-VGF-C antibody were blotted and probed by the respective
antibodies, anti-NERP-2 (a) or anti-VGF-C (b). 1: Synthetic peptide
(a: big NERP-2, 200 fmol, b: VGF[556–617], 50 fmol), 2: Affi-Gel Hz
hydrazide gel without tissue extract, 3: cerebral cortex, 4: hypothal-
amus, 5: pituitary intermediate/posterior, 6: pituitary anterior, 7:
jejunum/ileum, 8: colon, 9: adrenal gland, 10: pancreas, 11: liver, and
12: NGF-stimulated PC12 cells (only in b). Bands indicated by
arrowheads (i–v) in (a) and (I–VI) in (b) were deduced as interme-
diates and peptides shown in (c). Tissue amounts loaded for inves-
tigating ir-NERP-2 and ir-VGF-C, shown by mg wet weight
equivalents, are as follows: cerebral cortex (100, 30), hypothalamus
(50, 15), pituitary intermediate/posterior (1, 0.3), pituitary anterior (10,
3), jejunum/ileum (100, 30), colon (100, 30), adrenal gland (50, 30),
pancreas (100, 30), and liver (100, 30). (c) Schematic representation
of prepro-VGF, major cleavage sites, and peptides and processed
intermediates. Gray bar indicates a signal peptide, and black vertical
bars indicate Arg or Lys residue. Processing sites predicted from the
peptides and intermediates identified or deduced in the present study
are indicated by arrows. Numbers on the arrows are N-terminal
residues generated by proteolytic processing except for N- and C-
termini. Striped boxes of 285–309 and 313–350 indicate NERP-1 and
NERP-2, respectively.
Journal Compilation ! 2010 International Society for Neurochemistry, J. Neurochem. (2010) 114 , 1097–1106
! 2010 The Authors
1104 | E. Mishiro-Sato et al.
AQEE-30	
LQEQ-19	
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TLQP-21/C3aR1 
TLQP-21 is a particularly interesting peptide to explore, due to the discovery of a receptor 
for the peptide in 2013. Utilizing CHO-K1 cells and mouse models, it was found that the 
G-protein coupled receptor complement C3a receptor-1 (C3aR1) is the receptor for TLQP-
21 (Hannedouche et al., 2013). The complement pathway is a component of the innate 
immune system, which is called into action by invading pathogens and endogenous 
signals indicating injury. The complement 3a receptor-1 (C3aR1) was originally identified 
as the cognate G-protein coupled receptor for complement component 3a (C3a), a 
member of the alternative complement pathway (Biryukov & Stoute, 2018; Guo et al., 
2010; Harboe & Mollnes, 2008). TLQP-21 and C3a have a competitive relationship at the 
same binding site within C3aR1 (Cero et al., 2014; Hannedouche et al., 2013). Activation 
of C3aR1 leads to leukocyte activation and chemotaxis and can mediate apoptotic cell 
death, demyelination, and activation of resting microglia and astrocytes (Peterson & 
Anderson, 2014). C3aR1 participates in microglial signaling under pathological conditions 
including neurodegeneration and virus-induced cognitive impairment (Lian et al., 2015; 
Vasek et al., 2016). C3aR1 has been localized to neurons, microglia, and cultured 
astrocytes via in situ hybridization (Davoust, Jones, Stahel, Ames, & Barnum, 1999). 
Although the complement system has been implicated in mechanisms of neuropathic pain, 
the potential relevance of C3aR1 in these processes has not been addressed.  						
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Purpose of Studies 
 
In summary, previous work from the Vulchanova lab found that the VGF peptide TLQP-21 
is involved in the development and maintenance of neuropathic pain following peripheral 
nerve injury. The relevance of the receptor for TLQP-21, C3aR1, in this process is 
unknown. The overarching goal of this thesis was to examine the involvement of C3aR1 
in peripheral and central models of neuropathic pain. The following chapters include the 
following goals:     
 
Chapter 1:  
Determine the cell type that expresses C3aR1, and characterize the activation of C3aR1 
by TLQP-21. Examine the involvement of TLQP-21/C3aR1 signaling in neuropathic pain 
following peripheral nerve injury, via in vivo, in vitro, and immunohistochemical 
approaches.  
 
Chapter 2:  
Extensively characterize pain-related behaviors following spinal cord injury in male mice, 
and establish the relationship between injury severity and sensory changes occurring 
following spinal cord injury.  
 
Chapter 3.  
Examine the involvement of C3aR1 signaling in neuropathic pain following spinal cord 
injury, via in vivo and immunohistochemical approaches. Characterize antisense 
oligonucleotide mediated knockdown of C3aR1 on pain-related behaviors following 
peripheral nerve injury and spinal cord injury in mice.
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CHAPTER 1 
EXPRESSION AND FUNCTION OF THE COMPLEMENT-3A RECEPTOR 
FOLLOWING PERIPHERAL NERVE INJURY 
Chapter 1 contains works previously published in Glia; First published 29 August 2017; 
https://doi.org/10.1002/glia.23208; Title: “Complement 3a receptor in dorsal horn 
microglia mediates pronociceptive neuropeptide signaling.” Only the portions that were 
performed by the author of this thesis were included in this chapter. Portions of the 
article reprinted with permission from Wiley Periodicals, Inc.  
The complement pathway is a component of the innate immune system, which is 
called into action by invading pathogens and endogenous signals indicating injury. The 
complement 3a receptor (C3aR1) was originally identified as the cognate G-protein 
coupled receptor for complement component 3a (C3a), a member of the alternative 
complement pathway (Mathern & Heeger, 2015). In addition to C3a, the receptor has 
another endogenous ligand, the neuropeptide TLQP-21 (Cero et al., 2014; Hannedouche 
et al., 2013). TLQP-21 is generated from the neurotrophin-inducible protein VGF 
(nonacronymic), which has been implicated in neuroplasticity associated with learning and 
memory, depression, and chronic pain (Bartolomucci et al., 2006; Hunsberger et al., 2007; 
La Croix-Fralish, Austin, Zheng, Levitin, & Mogil, 2011; Lin et al., 2015; Moss et al., 2008; 
Riedl et al., 2009; Thakker-Varia et al., 2007). TLQP-21 and C3a have a competitive 
relationship at the same binding site within C3aR1 (Cero et al., 2014; Hannedouche et al., 
2013).  
Spared nerve injury (SNI) is a well characterized model of peripheral nerve injury-
induced neuropathic pain (Decosterd & Woolf, 2000). In this injury, the three branches of 
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the sciatic nerve are exposed. The peroneal and tibial nerves are ligated and cut, and the 
sural nerve is left intact. Following this injury, subjects develop mechanical 
hypersensitivity in the ipsilateral hindpaw, in the lateral portion of the hindpaw which is 
innervated by the sural nerve (Bourquin et al., 2006; Decosterd & Woolf, 2000). This 
hypersensitivity is reproducible and long-lasting in mice and rats. TLQP-21 modulates 
nociceptive signaling and nerve injury-induced hypersensitivity through both peripheral 
and spinal mechanisms (Chen et al., 2013; Fairbanks et al., 2014; Rizzi et al., 2008). Our 
lab previously demonstrated that TLQP-21 elicits hyperalgesia and participates in SNI-
induced hypersensitivity through an unknown mechanism in the spinal cord (Fairbanks et 
al., 2014).  
Microglial signaling is a crucial factor in the response of the central nervous system 
(CNS) to injury and disease. In the dorsal horn, microglia mediate neuroinflammation in 
chronic pain states such as neuropathic pain (Ji, Xu, & Gao, 2014; Taves, Berta, Chen, & 
Ji, 2013).  Following SNI, there are a number of immunohistochemical changes in the 
dorsal horn of the L3/L4 spinal cord, where the axons of the sciatic nerve terminate (Corder 
et al., 2010; Sorge et al., 2011). Microglial immunoreactivity (Iba1-ir) is increased 
specifically in the medial and central portion of the dorsal horn in the L3-L4 sections of the 
spinal cord (Corder et al., 2010). C3aR1 has been localized via in situ hybridization to 
neurons, microglia, and cultured astrocytes (Davoust, Jones, Stahel, Ames, & Barnum, 
1999). Additionally, C3aR1 participates in microglial signaling under pathological 
conditions including neurodegeneration and virus-induced cognitive impairment (Lian et 
al., 2016; Vasek et al., 2016). Although the complement system has been implicated in 
mechanisms of neuropathic pain (Griffin et al., 2007; Liu et al., 1995; Twining et al., 2005), 
the potential relevance of microglial C3aR1 has not been addressed.  
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In the following experiments, we utilized immunohistochemistry to visualize 
C3aR1-ir in the spinal cord of naïve mice and determined the localization of C3aR1 
protein. Using microglial cultures, we showed that TLQP-21 activated C3aR1 located on 
microglia. We probed changes in C3aR1 expression following spared nerve injury, and 
showed that C3aR1 signaling is important in the maintenance of hypersensitivity after 
injury.  
 
 
Methods: 
Animals: All work with animals adhered to the guidelines of the Committee for Research 
and Ethical Issues of the International Association for the Study of Pain and was approved 
by the Institutional Animal Care and Use Committee at the University of Minnesota in 
accordance with American Veterinary Medical Association guidelines. ICR/CD-1 outbred 
mice were purchased from Envigo (Indianapolis, USA). C3aR1 knock-out mice on a 
Balb/cJ background and wild-type Balb/cJ were obtained from Jackson Labs (# 005712). 
 
Spared Nerve Injury (SNI) model: The spared nerve injury model is a well-established 
model that produces substantial and prolonged changes in mechanical sensitivity and 
cold responsiveness that closely mimic the cutaneous hypersensitivity associated with 
clinical neuropathic pain (Decosterd & Woolf, 2000). SNI or sham surgery were 
performed under isoflurane anesthesia as described (Bourquin et al., 2006). For RNA 
analysis and immunohistochemistry, SNI was performed at 35 days of age. For qPCR, 
mice were sacrificed at 2 weeks post-surgery, and fresh tissue was collected for RNA 
extraction. To assess the time course of C3aR1 expression following peripheral nerve 
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injury, mice were sacrificed by transcardial perfusion at 3, 14, and 28 days post-surgery.  
 
Von Frey mechanical allodynia testing: Mechanical withdrawal thresholds for the hindpaw 
were measured at baseline and on Day 42 post-surgery by an experimenter blind to 
condition. Mice were acclimated at least 30 minutes in the testing environment within a 
glass cup on a raised metal mesh platform. To evaluate mechanical threshold we utilized 
a logarithmically increasing set of 8 von Frey filaments (Stoelting, Wood Dale, IL), ranging 
in gram force from 0.007 to 6.0 g. These were applied perpendicular to the medial hindpaw 
surface with sufficient force to cause a slight bending of the filament. A positive response 
was characterized as a rapid withdrawal of the paw away from the stimulus fiber within 4 
s. Using the up-down statistical method (Bonin, Bories, & De Koninck, 2014; Chaplan, 
Bach, Pogrel, Chung, & Yaksh, 1994), the withdrawal threshold was calculated for each 
mouse and then averaged within the experimental groups.  
Real-time quantitative PCR (qPCR): Two weeks post-surgery, spinal cords were removed 
via hydraulic extrusion. The lumbar enlargements were dissected and split along the mid- 
line into ipsilateral and contralateral halves relative to the peripheral injury. After 
homogenization, RNA was extracted with the Qiagen RNA Easy Lipid Mini Kit (Qiagen) 
and purified with the TURBO DNA free kit (Thermo Scientific). cDNA was generated with 
the Roche Transcriptor First Strand cDNA synthesis kit (Roche), and quantitative real-
time PCR was performed on a LightCycler 480 machine using primers for C3aR1 and 
GAPDH and the Roche LightCycler 480 SYBR Green Mas- ter Mix (Roche). Primer 
sequences were: C3aR1: 5-ACAAGTGAGACCAAGAATGACC-3 and 5-
GATTCCATCTCAGTGTGCTTG-3.  GAPDH: 5-GTGGAGTCATACTGGAACATGTAG-3  and 
5 -AATGGTGAAGGTCGGTGTG-3 .  DDCT values were  calculated  for  each  condition  
using sham contralateral as the control group. Fold changes (2DDCT) for each group were 
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compared with a one-way ANOVA, followed by Tukey’s post hoc test. 
Immunohistochemistry: Mice were deeply anesthetized with isoflurane and perfused via 
the heart with calcium-free Tyrode’s solution (in mM: 116 NaCl, 5.4 KCl, 1.6 MgCl-6H20, 
0.4 MgSO-7H20, 1.4 NaH2PO4, and 26 Na2HCO3) followed by fixative (4% 
paraformaldehyde and 0.2% picric acid in 0.1M phosphate buffer, pH 6.9). Tissues were 
dissected, incubated in 10% sucrose overnight at 48C, and then cryostat-sectioned (14 
μm) and thaw-mounted on to gelatin-coated slides. Sections were preabsorbed in 
blocking buffer (PBS containing 0.3% Triton-X 100, 1% BSA, 1% normal donkey serum) 
for 30 min, incubated in primary anti- bodies overnight at 48C, rinsed with PBS 3 x 10 
min, incubated in secondary antisera (1:300, Jackson ImmunoResearch, West Grove, CA) 
for 1 h at room temperature, washed with PBS, and coverslipped using PBS/glycerol 
containing 0.1% p-phenylenediamine (Sigma). Primary antibodies included: rat anti-
C3aR1 (1:100, Hycult Biotech), rabbit anti-Iba1 (1:1000; Wako Chemicals), goat 
anticollagen IV (1:2500, SouthernBiotech), mouse anti-GFAP (1:1000, Sigma), mouse 
anti- MAP2 (1:5000; Millipore), and rabbit anti-NeuN (1:1000, Cell Signaling). Images 
were collected with an Olympus FluoView1000 confocal imaging system. Adjustments 
of contrast and brightness were performed in Adobe Photoshop CS5; images from wild 
type and knockout mice were adjusted identically. For quantification of colocalization of 
Iba1 and GFP labeling in Iba1-eGFP mice, images of dorsal horn were collected as z-
stacks (6 optical sections, 1 μm apart) and projected in Image J. Three nonadjacent 
sections of lumbar spinal cord were imaged for each subject (n = 3). The projected 
images were thresholded above the level of background staining intensity, using the 
same threshold value for all Iba1 and GFP images, respectively. Stacks of 
corresponding Iba1 and GFP images were created in Image J. Cellular profiles, identified 
based on the presence of a soma-like structure with associated processes, were outlined 
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and assessed for presence of Iba1 and GFP labeling. Labeled profiles were counted, 
and the average number of double-labeled and single-labeled profiles per section was 
calculated for each subject. For quantitative image analysis of C3aR1-ir, single optical 
sections of C3aR1/Iba1/MAP2 triple-labeling were collected using constant image 
acquisition settings. Iba1 staining was used for unbiased selection of the focal plane. 
Analysis was performed in ImageJ. MAP2 labeling was used for reproducible outlining 
of a region of dorsal horn that included laminae I–III. To measure the area of C3aR1 and 
Iba1 labeling, the images were thresholded by a blinded experimenter. Analysis by three 
different blinded experimenters yielded reproducible results. C3aR1 and Iba1 labeling 
was expressed as % thresholded area. Data from three nonadjacent L3/L4 sections 
were averaged from each spinal cord.  
Primary microglial cultures: Cortical cells were collected from postnatal day 1–3 mouse 
pups of both sexes (CD-1, Charles River; Balb c/J wild-type or C3aR1 knock- out, Jackson 
Laboratory) and plated under conditions that promote survival of microglia and astrocytes 
but not neurons (Skaper, Argentini, & Barbierato, 2012). Mixed glial cultures were 
maintained in EMEM 1 10% fetal bovine serum (FBS) 1 1% L-glutamine 1 1% Penstrep 
(EMEM, 500 mL, Gibco; FBS, Gibco, 26140–079; L-glutamine, 200 mM, Thermo Fisher; 
Penstrep, Gibco) at 378C. After approximately 2 weeks, the flasks were shaken at 200 
rpm for 1.5 h to detach microglia. Each flask contained cells from approximately two pups 
and yielded approximately four coverslips. Cells were plated on 25 mm coverslips coated 
with poly- D-lysine (Sigma) at a density of 45,000 cells per coverslip. Cells were kept at 
37°C for 72 h prior to calcium imaging. The primary cultures consisted of approximately 
98% microglia. 
 
Calcium imaging: Cultured primary microglia were used 72 h after plating. Coverslips were 
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incubated with the ratiometric intracellular calcium indicator Fura-2 AM (Invitrogen) at a 
final concentration of 1.5 mM in HEPES buffer containing 1% bovine serum albumin for 
20 min prior to calcium imaging. Coverslips were then transferred to a recording chamber 
and perfused at a rate of 1.8 mL/min with HEPES–Hank’s buffer (25 mM HEPES, 135 mM 
NaCl, 2.5 mM CaCl2, 3.5 mM KCl, 1 mM MgCl2, and 3.3 mM glucose, pH 7.4 and 335–
340 mOsm adjusted with sucrose). A single field of view containing approximately 8 cells 
was imaged in each coverslip. Experimenters chose fields of view based on microglia cell 
morphology, such as resting elongated cells and rounded cells. Cells were exposed to 
100 mM ATP at 60 s and 10 mM TLQP-21 at 660 s during the recording session. Excitation 
wavelengths of 340 and 380 were used to measure bound and unbound calcium, 
respectively, in order to examine calcium flux. Excitation wavelengths and shutter speed 
were controlled by a DeltaRam X controller and LPS-220B lamp (PTI). ImageMaster 5.0 
software (PTI) was used to collect and analyze all images. Ratios of 340/380 were 
calculated and differences between the amplitude ratios at baseline and at peak after 
stimulation were measured in each cell within the field of view. Cells were considered 
responsive to ATP or TLQP-21 if the peak amplitude was twofold greater than noise, 
defined as the difference between the maximum and minimum baseline values during the 
10-s period preceding drug application. Three to five coverslips were tested from three 
CD-1 WT, three C3aR1 WT, and three C3aR1 KO cultures. Cells were grouped into 
responders or nonresponders in a contingency table for each treatment and were 
compared using Fisher’s exact test. 
Statistical Analyses: Data are expressed as the mean ± SEM, with p < .05 as significant. 
p values were determined using t-tests for two-group analysis, and 1- or 2-way ANOVA 
with repeated measures followed by pairwise comparisons using GraphPad Prism 
software (version 6; GraphPad Software, San Diego, CA). Proportions of profiles/cells 
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were compared using Fisher’s exact test. 
 
Results: 
C3aR1 is expressed in spinal microglia: 
 
 Although C3aR1 mRNA transcripts have been localized to neurons, astrocytes, and 
microglia in spinal cord (Davoust, Jones, Stahel, Ames, & Barnum, 1999), much less is 
known about the spinal distribution of C3aR1 protein. To fill this gap, we characterized a 
C3aR1 antibody with immunohistochemistry of spinal cord sections. Figure 1 
demonstrates C3aR1 immunoreactivity (–ir) on fine, short processes and a few cellular 
profiles throughout the spinal cord, including in the dorsal and ventral horn as well as in 
the white matter. C3aR1-ir was absent in C3aR1 knockout mice, demonstrating antibody 
specificity (Figure 1.1a,b). Double labeling for C3aR1 and Iba1, a marker of macrophages 
and microglia, indicated that C3aR1-ir was almost exclusively associated with microglia 
(Figure 1.1c–h, arrowheads). Intense C3aR1 labeling was also present in Iba1-positive 
meningeal/subarachnoid macrophages located within the pia mater or in close apposition 
to subarachnoid blood vessels, as indicated by their proximity to collagen IV-ir (Urabe et 
al., 2002) (Figure 1.1c–h, arrows; Figure 1.1i).  
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Figure 1.1: Spinal localization of C3aR1. (a, b) C3aR1 immunolabeling in superficial 
dorsal horn from wild-type (WT) and knock-out (KO) mice (DR indicates dorsal roots). The 
arrow in A indicates a cellular profile that is outlined by C3aR1 immunoreactivity (–ir). Scale 
bar: 50 μm. (c–h) Immuno-histochemical analysis of C3aR1-ir (red) and its relationship to 
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Iba1-ir (green) in dorsal horn. The dorsolateral region of the spinal cord in c–e is shown 
at higher magnification in f–h; e and h represent digital merging of c, d and f, g, 
respectively to show colocalization of labeling. C3aR1 and Iba1-ir overlap in fine 
processes and cellular profiles in superficial dorsal horn (f–h, arrowheads indicate the 
same cellular profile). Arrows in c–h indicate C3aR1/Iba1-positive profiles at the spinal 
cord perimeter. The image shown in f–h represents a projection of 3 optical sections, 1 μm 
apart. Scale bars: c–e, 75 μm; f–h, 25 μm. (i) C3aR1/Iba1-positive profiles at the spinal cord 
perimeter are associated with collagen IV (Coll) labeling that delineates the pia mater and 
subarachnoid blood vessels (VH indicates ventral horn; * indicate subarachnoid blood 
vessels). The spinal cord perimeter is shown at higher magnification in (I1–4). The arrows 
indicate the same region in I and I1–4. Scale bars: I, 100 μm; I1–4, 50 μm.  
 
 
TLQP-21-evoked Ca21 signaling occurs in microglia: imaging in microglial 
cultures: 
 
Following our localization of C3aR1 to microglia in the spinal cord, we aimed to 
determine whether TLQP-21 is able to directly activate microglia. We evaluated Ca2+ 
signaling in cortical microglial cultures prepared from neonatal CD-1 mice (P1–3). To 
restrict our analysis of TLQP-21-evoked responses to viable microglia, we used ATP as 
a reliable stimulus for microglial Ca2+ signaling (Wang, Kim, van Breemen, & McLarnon, 
2000). Cells were considered responsive to ATP or TLQP-21 if the peak amplitude was 
twofold greater than noise. We found that all TLQP-21-responsive cells were ATP- 
responsive (representative trace shown in Figure 1.2a). As illustrated by the scatterplots 
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of peak response amplitudes, of 97 cells found to be ATP-responsive, 37 also responded 
to TLQP-21, while 60 did not (Figure 1.2b). To determine if these responses were 
mediated by C3aR1 activation, we tested the effects of the R21A analog. In these 
experiments, of 78 cells found to be ATP-responsive, only 5 responded to R21A, while 
73 did not. Statistical analysis indicated that a significantly lower proportion of cells 
responded to R21A (6%) compared to TLQP-21 (38%) (p < .0001, Fisher’s exact test). 
 
We next compared TLQP-21 responses in microglial cultures taken from either C3aR1 
knock-out (KO) mice or their Balb/cJ wild-type (WT) controls. Figure 1.2c and d show 
scatterplots of peak response amplitudes for ATP and TLQP-21 for responders and 
nonresponders in WT and KO microglial cultures. Similar proportions of WT (90%) and 
KO (87%) cells responded to ATP. In contrast, the proportions of TLQP-21 responsive 
cells in WT (65%) and KO (5%) cultures differed significantly (p < .0001, Fisher’s exact 
test). Taken together, these experiments demonstrate that TLQP-21 directly activates 
C3aR1- dependent Ca21 signaling in microglia. 
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Figure 1.2: TLQP-21 activates C3aR1 in cultured primary microglia. (a) Representative 
ratiometric (D340/380 nm) traces of ATP (100 𝜇M) and TLQP-21 (10 𝜇M)-evoked Ca2+ 
transients in microglial cells isolated from P1–3 neonatal brain from wild-type (WT) mice. 
(b) Scatter plot of peak response amplitudes to TLQP-21 and R21A in wild-type 
cultures demonstrates that the proportions of TLQP-21 and R21A responders and 
nonresponders are significantly different (p < .0001, Fisher’s exact test). (c) Scatter 
plot of peak response amplitudes to ATP in cultures from WT and C3aR1 KO mice 
shows that the proportions of ATP responders and nonresponders in WT and KO 
cultures are not significantly different. (d) Scatter plot of peak response amplitudes 
to TLQP-21 in cultures from C3aR1 KO and WT mice shows that the proportions of 
TLQP-21 responders and nonresponders in WT and KO cultures are significantly 
different (p < .0001, Fisher’s exact test). 
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Each symbol in b–d represents a cell [Color figure can be viewed at 
wileyonlinelibrary.com] 
 
 
C3aR1 contributes to peripheral nerve injury-induced hypersensitivity: 
 
Intrathecal administration of TLQP-21 induces a transient, prostaglandin-dependent 
heat hyperalgesia in the warm water tail immersion assay (Fairbanks et al., 2014). 
Preliminary data from the lab (collected by KK) found that an antagonist to C3aR1, 
SB290157, had no behavioral effect when injected alone, but dose-dependently (0.1–
1.0 nmol) inhibited the hyperalgesia induced by TLQP-21. We previously used an 
immunoneutralization approach to demonstrate that TLQP-21 is necessary for nerve 
injury-induced hypersensitivity (Fairbanks et al., 2014). To determine whether C3aR1 
signaling is necessary as well, we evaluated the effect of SB290157 in the SNI model of 
neuropathic pain. SB290157 (1 nmol, i.t.) reversed mechanical hypersensitivity as 
compared to vehicle (Figure 1.3c; p < .01 at 30 min post-drug, p < .05 at 2 h post-drug, 
two-way repeated measures ANOVA and Bonferroni’s post hoc test). 
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Figure 1.3:  C3aR1 mediates peripheral nerve injury-induced hypersensitivity. The 
reduction in mechanical withdrawal thresholds after SNI is partially reversed by 
SB290157. **p < .01 at 30 min, *p < .05 at 2 h after drug treatment, two-way 
repeated ANOVA, followed by Bonferroni post hoc test. Data represent mean ± 
SEM 
 
 
 
Peripheral nerve injury increases the spinal expression of C3aR1 in a time-
dependent manner:  
 
Due to the prominence of immune activation following injury, and the contribution of 
microglia to neuropathic pain in animal models of peripheral nerve injury, we tested the 
hypothesis that spared nerve injury (SNI) increases the expression of C3aR1 in the 
dorsal horn. As illustrated in Figure 1.4a, 14 days after SNI we observed an 
approximately twofold increase in C3aR1 mRNA in the ipsilateral spinal cord (2.22 ± 
	 26	
0.2) as compared to the contralateral side of SNI mice (1.33 ± 0.25) or the ipsilateral 
(1.31 ± 0.21) or contralateral (1.07 ± 0.13) spinal cord of sham mice (p < .001, n = 14–
16 mice/ group; one-way ANOVA followed by Tukey’s multiple comparisons test). To 
determine the time course of the increase in spinal C3aR1 expression, we measured the 
area of C3aR1 labeling in dorsal horn at 3, 14, and 28 days after SNI or sham surgery 
(Figure 1.4b). The maximum increase in C3aR1-ir, relative to sham, was observed 3 
days after nerve injury. Although the labeling progressively decreased at 14 and 28 days 
post-surgery, C3aR1 expression remained elevated in the medial portion of dorsal horn 
as compared to control (Figure 1.4c–h). 
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Figure 1.4: Spinal expression of C3aR1 increases after nerve injury. (a) Real-time qPCR 
analysis demonstrates an increase in expression of C3aR1 mRNA in the ipsilateral spinal 
cord 14 days after SNI (n = 10–13 mice/group. *p < .05, one-way ANOVA followed by 
Tukey’s post hoc test; data represent mean ± SEM). (b) Quantitative analysis of C3aR1 
immunolabeling indicates that maximum increase in C3aR1 expression occurs 3 days 
post-surgery (p < .1 at day 3, p < .05 at day 14, p 5 .06 at day 28; t test). (c–h) 
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Representative images illustrate the increase in C3aR1-ir at days 3 (C, sham; D, SNI), 14 
(E, sham; F, SNI), and 28 (G, sham; H, SNI) after nerve injury. Scale bar: 100 μm. 
 
 
C3aR1 is primarily localized to microglia or macrophages after nerve injury:  
 
Having established that C3aR1 is expressed in microglia in the spinal cord in naïve 
animals, we next used double-label immunohistochemistry to confirm that C3aR1 
immunoreactivity (-ir) is not expressed in neurons or astrocytes in the dorsal horn 
following SNI. We found that C3aR1-ir was extensively co-localized with Iba1-ir at all 
time points examined (14 days post-surgery shown in Figure 1.5a). In contrast, C3aR1-
ir did not co-localize with either the astrocyte marker GFAP or the neuronal marker NeuN 
(Figure 1.5b,c). These data indicate that the expression of C3aR1 is limited to microglia, 
with no evidence of expression in spinal astrocytes or neurons, in the setting of nerve 
injury.  
 
 
	 29	
 
Figure 1.5: Spinal C3aR1-ir is localized in microglia after nerve injury. Double-labeling 
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for C3aR1 (red) and Iba1 (green, a), GFAP (green, b), and NeuN (green, c) in ipsilateral 
lumbar dorsal horn of SNI mice 14 days postsurgery. C3aR1-ir in dorsal horn colocalizes 
with Iba1-ir but not GFAP or NeuN-ir. Scale bar: 100 μm for a–c, 50 μm for a1–3, b1–3, 
c1–3 
 
 
Discussion 
 
C3aR1 has emerged as a neuro-glial mediator that contributes critically to pathological 
processes in the CNS by regulating neuroinflammation as well as neuronal structure and 
function (Lian et al., 2015; Vasek et al., 2016). We previously demonstrated that the 
newly identified ligand of C3aR1, TLQP-21, elicits hyperalgesia and participates in the 
development and maintenance of nerve injury-induced hypersensitivity (Fairbanks et al., 
2014). Here we examined the interaction of TLQP-21 and C3aR1, and provide the first 
evidence that microglial C3aR1 mediates the effects of TLQP-21 within the central 
nervous system.  
 
TLQP-21 directly targets C3aR1 to activate microglia  
We provide functional and anatomical evidence that microglia are the predominant 
cellular target for the effects of TLQP-21. First, we demonstrate extensive C3aR1 co-
localization with Iba1-ir microglia in the dorsal horn. Our co-localization analysis of C3aR1, 
GFAP, and NeuN labeling did not yield evidence for C3aR1 expression in astrocytes or 
neurons; however, we cannot rule out a secondary contribution of activation in neurons 
and/or astrocytes.   Second, the absence of TLQP-21-elicited Ca2+ transients in C3aR1 KO 
mice and in WT cultures exposed to R21A reinforces the evidence that TLQP-21 signaling 
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is C3aR1-mediated. 
C3aR1 in peripheral injury-induced spinal neuroplasticity 
Using immunoneutralization, we previously demonstrated that endogenous spinal TLQP-
21 contributes to the development and maintenance of nerve injury-induced 
hypersensitivity (Fairbanks et al., 2014). We examined the contribution of the receptor to 
hypersensitivity following SNI, and found that administration of a C3aR1 antagonist was 
able to attenuate the maintenance of mechanical allodynia. Our studies utilizing microglial 
cultures identify microglial C3aR1 as the target for TLQP-21. Since the TLQP-21 
precursor VGF is upregulated in sensory neurons within 24 h of nerve injury (Riedl et al., 
2009), spinal TLQP-21 released from injured sensory neurons is positioned to function as 
an endogenous danger signal that contributes to spinal neuroinflammation after nerve 
injury through activation of C3aR1. Little is known about the spinal availability of the 
originally characterized C3aR1 ligand C3a. Although expression of C3, the precursor of 
C3a, emerges in spinal microglia three days after peripheral nerve injury (Gattlen et al., 
2016; Griffin et al., 2007; Liu et al., 1995; Twining et al., 2005), the generation of C3a or 
its contribution to hypersensitivity remains to be established. 
 
We examined C3aR1 expression in the lumbar dorsal horn following peripheral nerve 
injury. Our results indicate a robust and early upregulation of C3aR1 specifically in 
microglia following peripheral nerve injury. This increase is highest during the acute 
phases of injury, steadily decreasing over time. These results point to a potentially 
important role in signaling through C3aR1 immediately following injury. In peripheral nerve 
injury, the increase in C3aR1 expression occurred in the area innervated by the central 
terminals of nociceptors for the ipsilateral hindpaw. This increase did not occur on the 
contralateral spinal cord or in sham controls, indicating a specific increase in complement 
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activation occurring following the unilateral nerve injury. Moreover, pharmacological 
inhibition of C3aR1 attenuated the behavioral hypersensitivity associated with SNI. These 
results provide the first evidence that microglial C3aR1 contributes to neuropathic pain. 
C3aR1 activation of monocytes induces release of ATP and cytokines (Asgari et al., 
2013). Spinal microglia also have the capacity to release ATP (Liu, Kalous, Werry, & 
Bennett, 2006), and microglial purinergic receptors are heavily implicated in neuropathic 
pain mechanisms (Beggs, Trang, & Salter, 2012). This leads us to speculate that the 
potential downstream consequences of C3aR1 signaling following peripheral and central 
injury include microglial release of ATP and cytokines, including mediators of spinal 
neuroplasticity such as IL-1b (Clark et al., 2015; Gruber-Schoffnegger et al., 2013). 
 
C3aR1 is expressed in meningeal/subarachnoid macrophages 
The present study makes the intriguing and novel observation that C3aR1 is expressed 
in meningeal/subarachnoid macrophages. It is well documented that macrophages can 
be found in mouse meninges and human cerebrospinal fluid, and that their number 
increases in pathological states such as multiple sclerosis (Chinnery, Ruitenberg, & 
McMenamin, 2010; Polfliet et al., 2001; Waschbisch et al., 2016). Thus, we suggest that 
C3aR1 is well-positioned to respond to complement pathway activation within the 
cerebrospinal fluid (e.g., in response to pathogens). Importantly, VGF fragments have 
been detected in multiple proteomic studies of human CSF (Bartolomucci et al., 2011). 
Therefore, we speculate that TLQP-21 acts at C3aR1 on macrophages in the CSF to 
promote neuroinflammation. Furthermore, since activated macrophages release 
prostaglandins that may diffuse within the spinal cord (Ulmann, Hirbec, & Rassendren, 
2010), C3aR1 receptors on CSF macrophages may provide insight into the mechanisms 
underlying the prostaglandin-mediated thermal hyperalgesia observed following 
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intrathecal injection of TLQP-21 (Fairbanks et al., 2014). 
 
In summary, we show that C3aR1 is localized to microglia in both naïve mice, and mice 
following peripheral nerve injury.  For the first time, we localized C3aR1 to subarachnoid 
macrophages, indicating that these complement receptor-expressing immune cells are 
located in a prime location for interaction with the spinal cord during neuropathic states. 
Previous work in our lab found that TLQP-21 evoked heat hyperalgesia is C3aR1-
dependent. Following spared nerve injury, an antagonist to C3aR1 was able to 
transiently attenuate mechanical hypersensitivity. Additionally, we found that TLQP-21 
specifically activates C3aR1 located on microglia. The identification of C3aR1 as the 
target of TLQP-21 suggests a novel interplay of neuronal and immune signaling 
mediators in CNS diseases. We identified that there is upregulation of C3aR1 in a time-
dependent manner following peripheral nerve injury. The early increase of receptor 
expression indicates a potentially important role of C3aR1 signaling throughout the acute 
stages of injury.  							
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CHAPTER 2 
COMPREHENSIVE CHARACTERIZATION OF SENSORY BEHAVIOR FOLLOWING 
A MOUSE MODEL OF SPINAL CORD INJURY 
 
Spinal Cord Injury (SCI) is a devastating condition with approximately 18,000 new injuries 
occurring each year in the U.S. The average age of SCI patients is 43 years old, and 78% 
of new injuries occur in males (National Spinal Cord Injury Statistical Center, 2019). The 
most common causes of SCI are vehicular accidents (38.3%), falls (31.6%), and violence 
(13.8%). The different types of spinal cord injuries are heterogeneous, with a mix of 
incomplete tetraplegia (47.2%), incomplete paraplegia (20.4%), complete paraplegia 
(20.2%), and complete tetraplegia (11.5%) (National Spinal Cord Injury Statistical Center, 
2019).  Complete spinal cord injuries leave patients with loss of motor and sensory function 
below the level of injury. Incomplete injuries are much more common, where some motor 
and sensory function is intact below the level of injury. The symptoms these patients 
experience differs depending on which portion of the spinal cord is affected. For example, 
a patient with damage mostly to the dorsal portion of the spinal cord is more likely to have 
sensory deficits or pain rather than motor symptoms. There are a number of chronic 
symptoms patients with spinal cord injuries experience. These include paralysis, loss of 
bladder or bowel control, altered sensation in extremities, muscle spasticity, difficulty 
breathing, chronic pain, and depression (Hagen, 2015; Sezer, 2015). 
 
Due to the lifelong impact of SCI, the economic and social costs to patients with SCI are 
staggering. Depending on the age at injury and level of the spinal cord, the lifetime costs 
of injury are between 1.6 and 4.9 million dollars (National Spinal Cord Injury Statistical 
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Center, 2019). The first year post-injury has the highest cost of treatment, due to the initial 
hospital stay and immediate rehabilitation. These estimates do not take into account the 
tens of thousands of dollars lost each year in un-or-under employment.  The life 
expectancy of patients with SCI is reduced, regardless of age at injury or injury level; the 
percent decrease in life expectancy scales to the severity of the injury (National Spinal 
Cord Injury Statistical Center, 2019).  
 
The prevalence of chronic pain in SCI patients is between 26%-96% (Dijkers, Bryce, & 
Zanca, 2009). Between 16%-63% of patients with chronic pain characterize it as severe 
(Bryce et al., 2012). The ranges are so variable due to the absence of a generalized 
classification system. There are a variety of types of chronic pain experienced by SCI 
patients, including nociceptive pain and neuropathic pain (Bryce et al., 2012; Nanna Brix 
Finnerup & Baastrup, 2012; Gorp, Kessels, Joosten, Kleef, & Patijn, 2014; Istituto & 
Biomediche, 2013). Nociceptive pain includes musculoskeletal and visceral pain, arising 
from the activation of nociceptors. Most nociceptive pain does not arise from the injury 
itself, but instead from the changes to bodily function and lifestyle that occur following a 
severe spinal cord injury (Bryce et al., 2012). These include difficulties in digestion and 
bladder function or strenuous use of particular muscles during movement, with or without 
mobility aides. Neuropathic pain typically includes at-level and below-level pain, and arises 
from damage to the spinal cord and spinal nerve roots. At-level pain is within the 
dermatome of injury to the spinal cord or spinal nerve roots, and can extend up to three 
dermatomes below the injury. Below-level pain is located more than three dermatomes 
below the injury, and is considered to be directly related to the injured spinal cord, rather 
than secondary injury. Common characteristics of neuropathic pain following SCI include 
sensory deficits within the pain distribution, allodynia or hyperalgesia, and descriptors of 
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the pain including: burning, tingling, pricking, sharp, squeezing, painful cold, and electric 
shocks.  
 
Neuropathic pain following SCI is particularly severe, long-lasting, and difficult to treat. In 
approximately 66% of patients with SCI neuropathic pain, current treatments, including 
pharmacological agents as well as physical therapy and electrical stimulation, fall short of 
achieving pain relief (Boldt et al., 2014; N. B. Finnerup & Jensen, 2004; Siddall, 
Mcclelland, Rutkowski, & Cousins, 2003). To address this critical need for effective pain 
management, it is important to elucidate the endogenous mechanisms that cause SCI 
neuropathic pain. The majority of animal studies examining pain behavior following spinal 
cord injury have been done in rats. Following thoracic contusion spinal cord injury, rats 
typically develop mechanical allodynia and thermal hyperalgesia (Hains, 2006a; Hama & 
Sagen, 2007; Peng et al., 2009; Sweitzer et al., 2006; Zhao et al., 2007a). Performing SCI 
in mice is more complex, due to their smaller size. It is important to utilize this model, as 
mice provide the potential for genetic manipulation that is more difficult in other species. 
Prior to the start of these experiments, there were limited studies examining pain-related 
behavior in mice following spinal cord injury (Hoschouer et al., 2010; Kerr & David, 2007; 
Meisner et al., 2010a). Our aim was to thoroughly characterize a range of locomotor, pain, 
and tactile behaviors following SCI utilizing a mild and moderate contusion injury. The 
following studies are the most thorough characterization of behavior following SCI in mice 
to date.  
 
 
 
 
	 37	
Methods: 
 
Spinal cord injury and postoperative care: All studies were approved by the University of 
Minnesota Institutional Animal Care and Use Committee (IACUC).  Thoracic spinal cord 
injury or sham surgery was performed on male ICR wild-type mice (Crl:CD1(ICR), Charles 
River, Wilmington, MA, USA) at 5 weeks of age. Prior to surgery, each subject was given 
0.5cc of sterile saline subcutaneously in each hindquarter. Briefly, a laminectomy was 
performed at T9, and the contusion injury was made with either 50 or 75 kdyn of force with 
the IH-0400 Infinite Horizons Impactor (Precision Systems and Instrumentation, LLC; 
Lexington, KY, USA) with a 1.3 mm mouse tip. Sham controls had a laminectomy at T9 
with no impact, and naïve subjects were housed in separate cages at the same time as 
their surgical counterparts. Animals received amoxicillin (14 g/L in drinking water) for 
7 days after surgery to prevent urinary tract infection as part of standard postoperative 
care. Urine was expressed manually twice daily for the first 7 days after surgery and daily 
thereafter until the return of independent urination. Experimental groups were as follows, 
listed in Table 2.1:  
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Functional assessment: Locomotor recovery following injury was assessed by two 
observers using the Basso Mouse Scale (BMS) (Basso et al., 2006), on days 1, 3, 5, 7, 
14, 21, 28, and 35 days following injury. Briefly, measurements were made on a 9-point 
scale derived from ankle movements, plantar/dorsal hindpaw stepping, coordination, trunk 
instability, and tail position. Mice were placed into an open field and monitored for five 
minutes each, with scores from 0 (complete paralysis) to 9 (normal locomotion) measured 
for each hindpaw. BMS scores were compared between treatments via repeated-
measures analysis of variance. 
  
Behavioral Testing: A number of behavioral tests were performed following sham or 
thoracic spinal cord injury beginning at 35 days post-injury and concluding at 45 days. 
These include:  
 
Rotarod: Mice were tested with the rotarod apparatus (Ugo Basile, Gemonio, Italy). 
Briefly, subjects were placed on an elevated rotating cylinder that increased in RPM 
continuously over 300 seconds, from 5 RPM to a peak of 50 RPM. RPM at fall was 
recorded for three consecutive days, beginning at Day 35 post-surgery.  No more than 
four subjects were tested at a time.  
 
Von Frey mechanical allodynia testing: Mechanical withdrawal thresholds for the 
hindpaw were measured at baseline and on Day 42 post-surgery by an experimenter blind 
to condition. Mice were acclimated at least 30 minutes in the testing environment within a 
glass cup on a raised metal mesh platform. To evaluate mechanical threshold we utilized 
a logarithmically increasing set of 8 von Frey filaments (Stoelting, Wood Dale, IL), ranging 
in gram force from 0.007 to 6.0 g. These were applied perpendicular to the medial hindpaw 
	 39	
surface with sufficient force to cause a slight bending of the filament. A positive response 
was characterized as a rapid withdrawal of the paw away from the stimulus fiber within 4 
s. Using the up-down statistical method (Bonin et al., 2014; Chaplan et al., 1994), the 
withdrawal threshold was calculated for each mouse and then averaged within the 
experimental groups.  
 
Hargreaves thermal hyperalgesia testing: Mice were tested for hindpaw thermal 
hyperalgesia using the IITC Plantar Test system at intensity: AI 30 (IITC Life Sciences, 
Woodland Hills, CA). Briefly mice were acclimated to an ambient floor (33°C) and a beam 
of focused light was aimed at each hindpaw. The length of time until paw withdrawal was 
measured. A humane cutoff time was automatically calibrated from the intensity settings. 
 
Burrowing behavior: Burrowing is an ethologically relevant behavior for mice, and 
others have utilized this as a measure of spontaneous pain following injury, which is 
improved with analgesic administration (R. M.J. Deacon, 2009; Robert M.J. Deacon, 2006; 
Jirkof, 2014; Jirkof et al., 2010). Briefly, a PVC tube with a cap at one end is elevated on 
the other end and filled with normal chow, and is placed in the home cage of each 
individually housed mouse. The amount of material burrowed during a 2-hour period is 
weighed, and then the remaining material in the tube is weighed. Data shown as (Material 
Burrowed)/(Total Material)*100 to get a burrowing percentage.  
 
Cotton swab test: The cotton swab test is a dynamic stroke assay designed to test 
light touch sensation (Garrison, Dietrich, & Stucky, 2011). This test utilizes a cotton swab 
puffed out to 3x its size, and the swab is brushed along the plantar surface five times with 
a 10-second break between applications, with the number of paw withdrawals recorded.  
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Results: 
 
We aimed to characterize a number of locomotor and pain-related behaviors following 
spinal cord injury. The results are collated into different groups, based on when the 
surgery was performed. This was due to improvement in surgical proficiency over time. 
Cohorts that occurred within several weeks of one another were combined. Some of this 
data is from experiments that had receptor knockdown via antisense oligonucleotides; 
to have enough SCI subjects for intervention they did not have sham controls. This 
chapter is presenting data from SCI subjects that received no intervention, or ones that 
received vehicle control injections. The results of the manipulations will be presented in 
chapter three.  
 
Male ICR mice recover locomotion following mild and moderate thoracic 
contusion spinal cord injury in a reproducible manner: 
 
Following contusion spinal cord injury, we assessed locomotor recovery with the Basso 
Mouse Scale (BMS). Testing occurred following SCI on days 1, 3, 5, 7, and then weekly 
for the remainder of the study. BMS is not designed as a linear scale, but rather follows 
the stereotypical sequence of recovery that occurs in mice following SCI (Basso et al., 
2006). Therefore, recovery over time does not tend to occur in a linear trajectory. 
Instead, scores tend to rapidly increase in the first few testing days, and then eventually 
plateau. Scores between (0-3) indicate hindlimb paralysis with variable amounts of ankle 
movement. Once subjects have reached between (4-6) on the scale, they are plantar 
stepping with variable coordination and foot placement. The 50 kdyn and 75 kdyn forces 
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were chosen so that we could characterize both a mild and a moderate-severe injury, in 
order to assess whether injury severity was a factor in the development of pain-related 
behaviors. 75 kdyn is considered a moderate-to-severe injury in mice (Kerr & David, 
2007; Orr et al., 2017; Zhang et al., 2015). In studies characterizing this injury as severe, 
mice recovered to an average of 3 on the BMS scale (Kerr & David, 2007). Our 75 kdyn 
mice recovered to an average between 4 and 5 on the BMS scale, so we categorized 
this group as moderately injured.  
 
Following mild or moderate injury, mice recover locomotor function in a stereotypical 
fashion, from low day one scores to a plateau occurring between 28 and 35 days post-
SCI. On day one after injury, there are a percentage of each cohort that have scores of 
4 or higher, indicating a less severe injury. As surgical proficiency improves, the 
percentage of mice that had higher scores on day 1 decreased. Throughout the rest of 
this chapter, results are presented in two ways: 1) all SCI mice for each cohort are 
averaged regardless of their BMS score on day one post-injury, and 2) SCI subjects are 
split between low and high day one BMS scores. A low score was between 0-3, and a 
high score was between 4-9.  
 
Table 2.2 illustrates the average BMS scores on day 1 and day 35 for the combined and 
split groups. A two-way ANOVA with repeated measures was run to assess significant 
differences over time between the low day one and high day one groups.  For all 50 kdyn 
cohorts, there were significant differences between the low and high day one BMS 
scores over time (p-values and F values reported in Table 2.2). The 75 kdyn group only 
had one animal with a BMS score of 4 or higher on day one, therefore no significant 
differences could be calculated between groups. We also examined whether the low and 
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high day one groups differed specifically on day 35 by utilizing Sidak’s multiple 
comparisons test. There were no significant differences between the low and high day 
one groups on day 35 for any of the cohorts, indicating that both groups ended up 
recovering to a similar BMS score prior to the start of behavioral testing (p-values 
reported in Table 2.2).  We also aimed to examine whether there were significant 
differences between all cohorts, specifically in the combined data. There were no 
significant differences in the two-way ANOVA (Fig. 2.1e; Time x Cohort, p= 0.807, 
F(14,168) = 0.664. Additionally, there were no significant differences at any of the 
timepoints measured between cohorts (Sidak’s multiple comparisons test).  
 
Table 2.2: BMS Scores  
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Figure 2.1: Male ICR mice recover locomotion following mild and moderate thoracic 
contusion spinal cord injury in a reproducible manner:  Mice had BMS scores taken on 
days 1, 3, 5, 7, and then weekly for the remainder of the studies. A-D(1-3): All cohorts, 
regardless of injury severity, exhibit stereotypical locomotor recovery, with lower scores 
on day one, rapid improvement between day one and day 14, and a plateau between 
day 28-35. Values on day one and day 35 are reported in Table 2.2. E: Comparisons of 
the combined data for the three 50 kdyn cohorts and the 75 kdyn cohort did not find 
significant differences between any of them (Two-way ANOVA with Sidak’s multiple 
comparisons (p= 0.807, F(14,168) = 0.664).  
  
 
Analysis of mild 50 kdyn thoracic contusion spinal cord injury effects on fine 
motor coordination in male ICR mice:  
 
We analyzed differences in fine motor coordination between sham and SCI mice with 
the rotarod apparatus. The mice we tested included the first and second 50 kdyn cohorts. 
There were no differences between the sham and SCI mice in either of the mild 50 kdyn 
cohorts that were tested (Fig. 2.2(a1,b1); p=0.835 and p=0.097 respectively, unpaired t-
test and one-way ANOVA). When the data was separated into two groups based on the 
BMS scores at day one, there were no differences between sham or any SCI group (Fig. 
2.2(a2,b2); p=0.704 and p=0.409 respectively, one-way ANOVA with Tukey’s post hoc). 
Even though the naïve mice exhibit higher RPM averages than the sham or SCI mice in 
the second 50 kdyn cohort, the differences were not significant (Tukey’s post hoc). We 
aimed to examine whether there were differences in rotarod performance based on the 
BMS score on day one post-injury. To do this we ran a correlation comparing day one 
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BMS score to the RPM at fall on testing day (Fig. 2.2(a3-b3)). The two mild injury cohorts 
had different relationships between day one BMS score and RPM, with the first 50 kdyn 
cohort having a negative correlation (r=-0.820) and the second 50 kdyn cohort having a 
positive correlation between the two variables (r=0.532).  
 
 
Figure 2.2: Analysis of mild 50 kdyn thoracic contusion spinal cord injury effects on fine 
motor coordination in male ICR mice:  We analyzed differences in fine motor 
coordination between sham and SCI mice with the rotarod apparatus. RPM at fall was 
recorded for three consecutive days, beginning at Day 35 post-surgery.  A1-B1: No 
significant differences between sham and SCI, or naïve, sham, or SCI in the rotarod test 
(p=0.835 and p=0.097 respectively, unpaired t-test and one-way ANOVA). A2-B2: SCI 
subjects were split into two groups based on their day one BMS score. There were no 
significant differences between sham and SCI, or naïve, sham, or SCI in the rotarod test 
(p=0.704 and p=0.409 respectively, one-way ANOVA with Tukey’s post hoc) A3: There 
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was a negative correlation between the RPM at fall and the day one BMS score (r=-
0.820) for the first 50 kdyn cohort, and (b3) a positive correlation between RPM at fall 
and the day one BMS score (r=0.532) for the second 50 kdyn cohort.  
 
 
Mechanical withdrawal thresholds are not altered following mild and moderate 
thoracic contusion spinal cord injury in male ICR mice:   
 
We utilized von frey filaments to test mice for mechanical sensitivity following mild and 
moderate injury. This assay was originally developed to test for pain-related behavior, 
where subjects with mechanical allodynia exhibit reduced withdrawal thresholds, 
measured in grams of force (Chaplan et al., 1994). In order to test for mechanical 
allodynia, the ability to detect stimuli within non-nociceptive ranges must be intact. 
Previous studies have found that the ability to detect stimuli for mechanical allodynia 
testing is variable in mice following contusion spinal cord injury (Hoschouer et al., 2010). 
For these experiments, mice from all three 50 kdyn cohorts and the mice from the 75 
kdyn cohort were tested. Our results indicate that regardless of the cohort, our injured 
subjects did exhibit changes in mechanical sensitivity. For each cohort, SCI mice 
consistently had higher thresholds than sham controls, and similar withdrawal thresholds 
to the naïve control mice. For the first and third 50 kdyn cohorts, there were no significant 
differences between sham and SCI or naïve and SCI subjects (Fig. 2.3(a1,c1); p = 0.258 
or p=0.228 respectively, unpaired t-test). Though the subjects in the low day one BMS 
score group tended to have higher withdrawal thresholds than the shams or subjects in 
the high day one score group when separated out, the differences were not significant 
(Fig. 2.3(a2,c2): p=0.170 and p=0.147, one-way ANOVA with Tukey’s post hoc). For the 
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second 50 kdyn cohort, the sham subjects had significantly reduced withdrawal 
thresholds compared to the naïve and SCI mice. This indicates that the laminectomy 
was potentially capable of eliciting mechanical allodynia, and that this did not occur in 
the SCI subjects (Fig. 2.3b1; p = 0.0071, one way ANOVA, tukey’s post hoc). When the 
subjects with low and high day one BMS scores were separated, there were significant 
differences between sham and high day one SCI mice, but not low day one SCI mice 
(p=0.009, one-way ANOVA with Tukey’s post hoc). The 75 kdyn cohort did not have any 
differences between naïve and SCI subjects, demonstrating that impact force does not 
elicit changes in mechanical sensitivity in our hands (Fig. 2.3d1; p=0.512, unpaired t-
test). This remained true when the subjects with low and high day one scores were 
separated (Fig. 2.3d2; p=0.805, one-way ANOVA with Tukey’s post hoc). Interestingly, 
when we ran correlations comparing BMS score on day one to withdrawal threshold, 
there was a consistent trend for all mild and moderate cohorts. For all cohorts, there was 
a negative correlation between withdrawal threshold and BMS score on day one, 
indicating that the more severely injured mice on day one have higher thresholds on 
testing day, and the less severely injured mice on day one have lower thresholds on 
testing day (Fig. 2.3(a3-d3): 50 kdyn cohort 1: r = -0.517; 50 kdyn cohort 2: r =-0.194; 50 
kdyn cohort 3: r = -0.366; 75 kdyn cohort: r = -0.184).  
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Figure 2.3: Mechanical withdrawal thresholds are not altered following mild and 
moderate thoracic contusion spinal cord injury in male ICR mice: At six weeks following 
thoracic contusion SCI, withdrawal thresholds were measured with von frey filaments. 
A1,C1: For the first and third 50 kdyn cohorts, withdrawal thresholds for SCI mice were 
unchanged compared to sham controls (p = 0.258 or p=0.228 respectively, unpaired t-
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test). A2,C2: When the injured subjects were split based on their day one BMS scores, 
there were no significant differences between groups (p=0.170 and p=0.147, one-way 
ANOVA with Tukey’s post hoc). B1: For the second 50 kdyn cohort, the sham subjects 
exhibited mechanical allodynia compared to the naïve and SCI mice (p = 0.0071, one 
way ANOVA, tukey’s post hoc). B2: When the injured subjects were split based on their 
day one BMS scores, sham had significantly lower thresholds compared to naïve and to 
the injured subjects with high day one BMS scores (p=0.009, one-way ANOVA with 
Tukey’s post hoc) D1-2: The moderate 75 kdyn cohort did not have different mechanical 
thresholds compared to sham controls (combined: p=0.512, unpaired t-test; separated: 
-p=0.805, one way ANOVA with Tukey’s post hoc). A3-D3: For all cohorts, there was a 
negative correlation between withdrawal threshold and BMS score on day one, indicating 
that the more severely injured mice on day one have higher thresholds on testing day, 
and the less severely injured mice on day one have lower thresholds on testing day (Fig. 
2.3(a3-d3): 50 kdyn cohort 1: r = -0.517; 50 kdyn cohort 2: r =-0.194; 50 kdyn cohort 3: 
r = -0.366; 75 kdyn cohort: r = -0.184). 
 
 
Following mild or moderate thoracic contusion spinal cord injury, injury severity 
measured on day one affects whether male ICR mice develop heat hyperalgesia: 
 
We assessed heat hyperalgesia with the Hargreaves apparatus, which utilizes a radiant 
heat source aimed toward the hindpaw. Subjects with heat hyperalgesia will exhibit 
reduced latency to withdraw from the light (Deuis, Dvorakova, & Vetter, 2017; 
Hargreaves, Dubner, Brown, Flores, & Joris, 1988). We performed this assay with the 
mice from the second and third 50 kdyn cohorts, and the 75 kdyn cohort. The second 50 
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kdyn cohort had no significant differences in withdrawal latencies between naïve, sham, 
or SCI mice regardless of if low and high day one BMS groups were combined or 
separated (Fig. 2.4(a1,2); p=0.775 and p=0.898 respectively, one way ANOVA with 
Tukey’s post hoc).  When the low and high day one groups were combined, the third 50 
kdyn cohort had differences approaching significance (Fig 2.4b1; p=0.083,  unpaired t-
test). When day one BMS scores were separated into low and high, the injured subjects 
with low day one scores had significantly lower withdrawal latencies compared to naïve 
mice, indicating thermal hyperalgesia (Fig. 2.4b2, p=0.015, one-way ANOVA with 
Tukey’s post hoc). For the moderate 75 kdyn contusion injury, there were no significant 
differences between naïve and injured mice (Fig. 2.4d1; p=0.388, Welch’s t-test 
separated). The high day one subject in the 75 kdyn cohort was statistically an outlier in 
the combined group, therefore examining differences based on low or high day one 
scores for this test are meaningless. We ran correlations comparing BMS score on day 
1 to withdrawal latency, and there was a consistent trend for all injuries regardless of 
impact force. For all cohorts, there was a highly positive correlation between withdrawal 
latency and BMS score on day one, indicating that the more severely injured mice on 
day one have lower latencies on testing day, and the less severely injured mice on day 
one have higher latencies on testing day (Fig. 2.4(a3-c3): 50 kdyn cohort 2: r = 0.752; 
50 kdyn cohort 3: r = 0.997; 75 kdyn cohort: r = 0.991). Our results point to thermal 
hyperalgesia developing in spinal cord injury subjects in a variable manner, with more 
severely injured mice on day one following SCI being more likely to exhibit reduced 
withdrawal latencies.   
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Figure 2.4: Following mild or moderate thoracic contusion spinal cord injury, injury 
severity measured on day one affects whether male ICR mice develop heat 
hyperalgesia: A1-C1: The mild 50 kdyn and moderate 75 kdyn injuries did not elicit heat 
hyperalgesia when day one groups are combined (a1-b1: p=0.775 and 0.083, one way 
ANOVA and unpaired t-test respectively; c1: p=0.388, Welch’s t-test).  B2: Subjects with 
low day one BMS scores have significantly lower withdrawal thresholds than naïve 
subjects on testing day (, p=0.015, one-way ANOVA with Tukey’s post hoc). C1-3: For 
all cohorts, there was a highly positive correlation between withdrawal latency and BMS 
score on day one, indicating that the more severely injured mice on day one have lower 
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latencies on testing day, and the less severely injured mice on day one have higher 
latencies on testing day (Fig. 2.4(a3-c3): 50 kdyn cohort 2: r = 0.752; 50 kdyn cohort 3: 
r = 0.997; 75 kdyn cohort: r = 0.991). 
 
 
Following mild or moderate thoracic contusion spinal cord injury, injury severity 
measured on day one affects how much male ICR mice burrow:  
 
Burrowing is an ethologically relevant behavior in mice, most frequently utilized as a 
model of overall well-being (R. M.J. Deacon, 2009; Robert M.J. Deacon, 2006; Jirkof, 
2014). Some have used this as a measure of spontaneous pain following injury, which 
is improved with analgesic administration (Andrews et al., 2012; Deuis et al., 2017; Jirkof 
et al., 2010). We tested burrowing behavior in all three 50 kdyn cohorts, and in the 75 
kdyn cohort. Our results indicate that in general, burrowing behavior is decreased in SCI 
mice. Though the trend of decreased burrowing in SCI subjects remains consistent 
regardless of injury severity, there are no significant differences in burrowing behavior 
between any of the groups tested when the subjects with low and high day one scores 
were combined (Fig. 2.5a1-d1; a1: p=0.354, unpaired t-test; b1: p=0.519, one way 
ANOVA with Tukey’s post hoc; c1: p= 0.109, Welch’s t-test; d1: p=0.164, unpaired t-
test). When subjects with low and high day one BMS scores are separated, there are 
significant differences that are uncovered. For the first 50 kdyn cohort, there are 
significant differences between the sham and low day one subjects, and between the 
low day one and high day one groups (p= 0.0104, one-way ANOVA with Tukey’s post 
hoc). This indicates that more severely injured subjects on day one end up burrowing 
less than less severely injured mice, regardless of if they have recovered similar 
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locomotion by testing day. These trends held for the other 50 kdyn cohorts and the 75 
kdyn cohort, even if they were not significantly different (Fig. 2.5b2-d2; ps>0.05, one-
way ANOVA with Tukey’s post hoc). Overall our results suggest a trend in reduced 
burrowing, which we presume might be due to reduced locomotion, reduced level of well-
being, or spontaneous pain-behavior. We ran correlations comparing BMS score on day 
1 to percent of material burrowed, and there was a consistent trend for all injuries 
regardless of impact force. For all cohorts, there was a highly positive correlation 
between burrowing percentage and BMS score on day one, indicating that the more 
severely injured mice on day one burrow less, and the less severely injured mice on day 
one burrow more (Fig. 2.4(a3-c3): 50 kdyn cohort 1 : r = 0.775; 50 kdyn cohort 2: r = 
0.336; 50 kdyn cohort 3: r = 0.995; 75 kdyn cohort: r = 0.889). 
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Figure 2.5: Following mild or moderate thoracic contusion spinal cord injury, injury 
severity measured on day one affects how much male ICR mice burrow:  The percentage 
of material burrowed during the burrowing assay was measured and compared between 
naïve, sham, and SCI mice. A1-D1: Though the trend of decreased burrowing in SCI 
subjects remains consistent regardless of injury severity, there are no significant 
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differences in burrowing behavior between any of the groups tested when the subjects 
with low and high day one scores were combined (A1: p=0.354, unpaired t-test; b1: 
p=0.519, one way ANOVA with Tukey’s post hoc; 1: p= 0.109, Welch’s t-test; d1: 
p=0.164, unpaired t-test). A2: For the first 50 kdyn cohort, there are significant 
differences between the sham and low day one subjects, and between the low day one 
and high day one groups (p= 0.0104, one-way ANOVA with Tukey’s post hoc). B2-D2: 
When low and high day one BMS groups were separated, there was a statistically 
insignificant trend towards decreased burrowing for more severely injured subjects on 
day one (ps>0.05, one-way ANOVA with Tukey’s post hoc). A3-D3: We ran correlations 
comparing BMS score on day 1 to percent of material burrowed, and there was a 
consistent trend for all injuries regardless of impact force. For all cohorts, there was a 
highly positive correlation between burrowing percentage and BMS score on day one, 
indicating that the more severely injured mice on day one burrow less, and the less 
severely injured mice on day one burrow more (Fig. 2.4(a3-c3): 50 kdyn cohort 1 : r = 
0.775; 50 kdyn cohort 2: r = 0.336; 50 kdyn cohort 3: r = 0.995; 75 kdyn cohort: r = 
0.889). 
 
 
Mild and moderate spinal cord injury induces a dramatic loss of light touch 
sensitivity in male ICR mice: 
 
The cotton swab test is used to examine changes in light touch sensitivity in the hindpaw, 
specifically sensitivity of low-threshold, rapidly adapting mechanoreceptors (Dhandapani 
et al., 2018; Garrison et al., 2011). We tested mice from the second and third 50 kdyn 
cohorts, and from the 75 kdyn cohort. For the second 50 kdyn cohort, the SCI mice had 
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significantly decreased responses when compared to the naïve or sham mice, which 
were not different from one another (Fig. 2.6a1; p=0.0003, one way ANOVA, Tukeys 
post hoc). These results did not change when subjects were split into low day one and 
high day one groups; both SCI groups had significantly reduced responses compared to 
sham and naïve mice (Fig. 2.6a2; p<0.0001, one-way ANOVA with Tukey’s post hoc). 
The third 50 kdyn SCI mice exhibited significantly decreased percent responses when 
compared to the naïve controls (Fig. 2.6b1; p=0.0006, unpaired t-test). When the 
subjects were separated based on day one BMS scores, only the group with low day 
one BMS scores were significantly different than naïve controls (Fig. 2.6b2; p=0.0008, 
one-way ANOVA with Tukey’s post hoc). The moderate 75kdyn contusion SCI subjects 
had significantly decreased responses compared to naïve control subjects, regardless 
of if subjects with low and high day one BMS scores were combined or separated (Fig. 
2.6c1-2; p=0.0115, Welch’s t-test or p = 0.0040, one-way ANOVA with Tukey’s post hoc, 
respectively). We ran correlations comparing BMS score on day 1 to percent responses, 
and there was not a consistent trend based on injury severity. (Fig. 2.6(a3-c3): 50 kdyn 
cohort 2 : r = -0.472; 50 kdyn cohort 3: r = 0.854; 75 kdyn cohort: r = -284). Overall, our 
results indicate that mice that underwent contusion spinal cord injuries exhibit significant 
decreases in responsiveness to the cotton swab stimulus. This indicates a significant 
loss of light touch sensitivity occurring in the spinal cord injury subjects, regardless of 
injury severity. 
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Figure 2.6: Mild and moderate thoracic contusion spinal cord injury induces a dramatic 
loss of light touch sensitivity in male ICR mice: We utilized the cotton swab test to 
examine changes in light touch sensitivity in the hindpaw. A1: For the second 50 kdyn 
cohort, SCI mice had significantly decreased responses when compared to the naïve or 
sham mice, which were not different from one another (Fig. 2.6a1; p=0.0003, one way 
ANOVA, Tukeys post hoc). A2: When subjects were split into low day one and high day 
one groups, both SCI groups had significantly reduced responses compared to sham 
and naïve mice (Fig. 2.6a2; p<0.0001, one-way ANOVA with Tukey’s post hoc). B1: The 
third 50 kdyn SCI mice exhibited significantly decreased percent responses when 
	 58	
compared to the naïve controls (Fig. 2.6b1; p=0.0006, unpaired t-test). B2: For the third 
50 kdyn cohort, when the subjects were separated based on day one BMS scores, only 
the group with low day one BMS scores were significantly different than naïve controls 
(Fig. 2.6b2; p=0.0008, one-way ANOVA with Tukey’s post hoc). C1-2: The moderate 
75kdyn contusion SCI subjects had significantly decreased responses compared to 
naïve control subjects, regardless of if subjects with low and high day one BMS scores 
were combined or separated (Fig. 2.6c1-2; p=0.0115, Welch’s t-test or p = 0.0040, one-
way ANOVA with Tukey’s post hoc, respectively). A3-C3: We ran correlations comparing 
BMS score on day 1 to percent responses, and there was not a consistent trend based 
on injury severity. (Fig. 2.6(a3-c3): 50 kdyn cohort 2 : r = -0.472; 50 kdyn cohort 3: r = 
0.854; 75 kdyn cohort: r = -284). 
 
 
Discussion 
 
Spinal cord injury is severe, long-lasting, and presents with a myriad of complications. 
Animals studies have aimed to examine SCI to investigate potential interventions, but 
many of these experiments have been done in rats. The present study aimed to thoroughly 
characterize behavior following mild and moderate thoracic contusion SCI in male ICR 
mice. These studies are the most thorough characterization of sensory behavior following 
SCI in mice to date, including touch, and evoked or spontaneous pain behaviors. We show 
for the first time that following SCI, mice exhibit a dramatic loss of light touch sensitivity.  
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Spinal cord injury induces a significant loss of light touch sensitivity in mice  
 
The cotton swab test was originally designed to complement a light touch punctate assay, 
intended as a more dynamic light touch stimulus (Garrison et al., 2011). It was developed 
to study the mechanosensitive ion channel TRPC1, which is primarily located on A-beta 
and peptidergic IB4-negative C-fibers (Elg, Marmigere, Mattsson, & Ernfors, 2007). The 
cotton swab assay was utilized to assess if there was an effect of TRPC1 knockdown on 
sensitivity of large diameter, low-threshold mechanosensory neurons (Garrison et al., 
2011). Following knockdown of TRPC1, there were decreased cotton swab responses. 
Another study examined the effect of ablating TrkB-positive sensory neurons, which are 
primarily myelinated low-threshold mechanoreceptors that innervate D-hairs and rapidly 
adapting mechanoreceptors (Dhandapani et al., 2018). Ablation of low-threshold afferents 
led to decreased cotton swab responses. These studies elucidate the mechanoreceptors 
that are activated by the cotton swab assay in naïve mice, specifically low threshold, 
rapidly adapting mechanoreceptors. Following intraplantar CFA or spared nerve injury, 
mice respond in higher percentages than vehicle-injected or sham mice (Cowie, Moehring, 
O’Hara, & Stucky, 2018). The cotton swab test is therefore a useful assay to test light 
touch sensitivity, which is able to detect mechanical allodynia in injury models.  
 
Though this test has been utilized on mice that have had inflammation or peripheral nerve 
injury, these studies are the first to utilize this assay to test light touch following spinal cord 
injury. Overall, the cotton swab test uncovered changes in light touch sensitivity that occur 
following spinal cord injury. SCI was capable of producing a significant decrease in 
responses when compared to naïve and sham mice. The near-complete absence of 
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responses to the stimulus seen in the SCI subjects points to a significant loss of their light 
touch sensitivity, specifically information sent from low-threshold rapidly adapting 
mechanoreceptors. These mice had the ability to plantar step, and even the most severely 
injured had withdrawal responses to noxious stimuli. Therefore, we concluded that the 
lack of withdrawal response to the cotton swab were indicative of reduced sensitivity rather 
than motor deficits.  
 
The loss of light touch sensitivity is consistent with what would be predicted to occur 
following dorsal column damage, a component of the contusion spinal cord injury.  The 
dorsal column-medial lemniscal pathway relays information sent from the periphery to the 
brain. The information carried through this pathway includes touch and proprioceptive 
information. In humans, spinal cord injury can lead to loss of sensation, with or without 
pain (Eide et al., 1996). In mice and rats, contusion spinal cord injury leads to a lesion in 
the spinal cord that encompasses the dorsal columns at the level of injury (Attwell, van 
Zwieten, Verhaagen, & Mason, 2018; James et al., 2011). This disrupts the flow of touch 
information being sent from the periphery. Electrophysiological recordings from teased 
dorsal root fibers found that following SCI, rats have a complete conduction block in 
ascending dorsal column axons during the acute phases of injury (James et al., 2011). 
Conduction across the lesion improves slightly over time, but still remains significantly 
reduced during the chronic phase of injury. Interestingly, though there were still a large 
number of demyelinated fibers in the dorsal columns during the chronic phase, there was 
a subpopulation of axons that remained myelinated but were unable to conduct action 
potentials (James et al., 2011). Our work points to the cotton swab assay being a useful 
test to measure changes in touch sensitivity following SCI in mice. In addition, due to the 
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potential presence of intact axons in this area that can be targeted with interventions to 
regain function, this assay is a potential tool to measure attenuation of these deficits. 
3 
Severity of injury influences pain-related behaviors following spinal cord injury in mice 
 
Our results examining mechanical sensitivity, thermal hyperalgesia, and burrowing 
behavior uncover the impact of injury severity following SCI on measures of pain-related 
behavior. Prior to the start of these studies, there were a limited number of studies that 
found mice with mechanical allodynia and thermal hyperalgesia following a variety of SCI 
methods, including clip compression and weight-drop contusion (Hoschouer, Yin, & 
Jakeman, 2009; Kerr & David, 2007; Meisner, Marsh, & Marsh, 2010b; Tanabe, Ono, 
Honda, & Ono, 2009). Prior to the conclusion of these studies, several papers were 
published confirming the development of thermal hyperalgesia following SCI in mice 
(Castany, Gris, Vela, Verdú, & Boadas-Vaello, 2018; Gensel, Donahue, Bailey, & Taylor, 
2019). Consistent with this work, we were able to detect thermal hyperalgesia in our spinal 
cord injury mice, particularly the subjects with more severe injury on day one. There was 
a highly positive correlation between BMS score on day one and withdrawal latency, with 
more injured mice on day one post-SCI exhibiting lower withdrawal latency.  
 
Evaluation of spontaneous or ongoing pain in mice is more difficult than measuring evoked 
responses, but methods have been adapted to evaluate behavior in models of persistent 
pain. In peripheral and inflammatory injury models, conditioned place preference has been 
utilized to assess ongoing pain, by measuring the preference of an injured subject for a 
chamber paired with a non-opioid analgesic (King et al., 2009; Okun et al., 2011; Sufka, 
1994). There are only a handful of studies utilizing conditioned place preference in spinal 
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cord injury, where they found evidence of ongoing pain in rats (Davoody et al., 2011; Yang 
et al., 2014). Burrowing is an ethologically relevant behavior that is considered a measure 
of overall well-being in mice (Robert M.J. Deacon, 2006; Jirkof, 2014). There are several 
groups that have found reduced burrowing in peripheral models of pain, which is 
attenuated by administration of an analgesic (Andrews et al., 2012; Deuis et al., 2017; 
Jirkof et al., 2010). These studies are the first to examine burrowing behavior in mice 
following spinal cord injury. Our results point to a consistent trend in decreased burrowing 
in spinal cord injured mice, that is highly correlated to injury severity on day one following 
SCI. These results are complex to draw conclusions from, due to the nature of spinal cord 
injury. It is possible that this reduced burrowing is indeed due to ongoing pain, but unless 
this behavior is reversed through administration of an analgesic, it is impossible to 
conclude that is the case. It is also possible that overall these mice are feeling ill, and 
therefore the reduced burrowing is due to a reduction in overall well-being. A complication 
with testing ongoing pain measures in spinal cord injury is the motor impairment that is a 
hallmark of the injury. It is possible that reduced burrowing is due primarily to reduced 
overall movement, even though these mice have recovered locomotion enough to perform 
the task. Future studies should take this into account when designing methods to probe 
ongoing pain in mice following spinal cord injury.  
 
We utilized von frey filaments to test mechanical sensitivity, and found that in general, SCI 
mice had higher thresholds than sham mice and similar thresholds to naïve controls. There 
was a consistent negative correlation between injury severity on day one post-SCI and 
withdrawal thresholds, with more severely injured mice having higher thresholds. This is 
in line with work by Hoschouer et al, where they found that SCI mice had higher hindpaw 
withdrawal thresholds than control mice, even though they responded to a pin-prick, which 
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is a noxious mechanical stimuli (Hoschouer et al., 2010). More recent work has found 
mechanical allodynia in mice following SCI, but importantly these injuries were specifically 
designed to not cause paresis, with BMS scores on day one hovering around 5.0 on the 
scale (Castany et al., 2018). These findings are in line with our work and the work by 
Hoschouer et al, indicating that injury severity is an important consideration when testing 
for mechanical allodynia in spinal cord injured mice. The Von Frey test was originally 
developed to assess mechanical allodynia (Chaplan et al., 1994), but in order to measure 
this, function of low threshold mechanoreceptors must be intact. Our work utilizing the 
cotton swab assay found a loss of light touch sensitivity, likely caused by a loss of 
information sent through low threshold rapidly adapting mechanoreceptors due to dorsal 
column damage. Recent work examining peripheral nerve injury has uncovered a role for 
the dorsal column pathway in transmitting mechanical allodynia, upending the long-
standing idea that pain primarily travels through anterolateral pathways, segregated from 
touch which is sent through the dorsal columns. Several groups have lesioned the dorsal 
column pathway following the establishment of mechanical allodynia and thermal 
hyperalgesia. One group reported a total loss of mechanical allodynia but not hyperalgesia 
24 hours after transecting the dorsal columns (H. Sun et al., 2001). Importantly, additional 
work found that there is recovery of mechanical allodynia several weeks after dorsal 
column lesion, indicating that though the dorsal columns are involved in transmission of 
mechanical allodynia, they are not solely responsible for the persistence of this behavior 
(Saadé et al., 2002). In patients with spinal cord injuries, there are a number that have 
loss of sensation without pain, pain without loss of sensation, or experience both 
simultaneously. Studies examining sensation in these patients concluded that central 
dysesthesia following spinal cord injury isn’t solely due to dysfunction of spinothalamic 
tract, and that there is potential involvement of dorsal column dysfunction as well ( Eide et 
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al., 1996; N. B. Finnerup, Johannesen, Fuglsang-Frederiksen, Bach, & Jensen, 2003). 
Overall, our results point to the absence of mechanical allodynia in our spinal cord injury 
mice, but whether this is due to the damaged dorsal columns or these mice do not have 
allodynia is unclear. Interestingly, in one of our cohorts we were able to elicit lowered 
withdrawal thresholds in sham control mice, which received the laminectomy without 
impact. These were significantly lower than both the naïve and the SCI mice, indicating 
mechanical allodynia. These results point to the importance of including both naïve and 
sham control mice when examining mechanical sensitivity following spinal cord injury.  
 
Another factor to consider is that the pain-related behaviors we were examining were 
exclusively looking at below-level pain. Following SCI, many patients have at-level 
neuropathic pain, described as pain within three dermatomes of the level of injury. There 
have been limited studies examining at-level pain in mice following spinal cord injury. One 
group found a marked decrease of responses to noxious pin-prick and non-noxious von 
frey filaments directly caudal to the injury site on the dorsal trunk (Hoschouer et al., 2010). 
These areas needed to be shaved, so that the testing site was visible, the area tested was 
reproducible, and so that responses were not due to activation of mechanoreceptors 
specifically innervating the hairs.  
 
Conclusions 
 
Overall, our findings point to a dramatic loss of light touch sensitivity following spinal cord 
injury in male mice, most likely caused by damaged dorsal columns disrupting the flow of 
information from low-threshold mechanoreceptors. Following spinal cord injury, male mice 
develop thermal hyperalgesia that is dependent on injury severity, and they burrow less 
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than sham or naïve controls. Interestingly, our mice did not develop mechanical allodynia 
following spinal cord injury, and this may also be mediated by the damage to the dorsal 
columns. These studies are the most thorough characterization of behavior following SCI 
in mice to date. 
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CHAPTER 3 
ANTISENSE OLIGONUCLEOTIDE-MEDIATED KNOCKDOWN OF COMPLEMENT-3A 
RECEPTOR 1: 
EFFECT ON PERIPHERAL AND CENTRAL MODELS OF NEUROPATHIC PAIN 
 
The complement pathway is a component of the innate immune system, which is called 
into action by invading pathogens and endogenous signals indicating injury. The 
complement 3a receptor (C3aR1) was originally identified as the cognate G-protein 
coupled receptor for complement component 3a (C3a), a member of the alternative 
complement pathway (Biryukov & Stoute, 2018; Harboe & Mollnes, 2008; Thurman & 
Holers, 2006). C3aR1 has been localized via immunohistochemistry to myeloid cells 
including microglia and macrophages (Doolen et al., 2017), and has been found in 
neurons and cultured astrocytes via in situ hybridization (Davoust et al., 1999). Activation 
of C3aR1 leads to leukocyte activation and chemotaxis and can mediate apoptotic cell 
death, demyelination, and activation of resting microglia and astrocytes (Peterson & 
Anderson, 2014). C3aR1 participates in microglial signaling under pathological conditions 
including neurodegeneration and virus-induced cognitive impairment (Hong et al., 2016; 
Lian et al., 2015; Vasek et al., 2016).  
 
In addition to C3a, the receptor has another endogenous ligand, the neuropeptide TLQP-
21, and these ligands have a competitive relationship at the same binding site within 
C3aR1 (Cero et al., 2014; Hannedouche et al., 2013). Our lab has found that TLQP-21 is 
involved in the development and maintenance of hypersensitivity following peripheral 
nerve injury, and that this may occur through the activation of microglia by TLQP-21 in a 
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C3aR1-dependent manner (Doolen et al., 2017; Fairbanks et al., 2014). Upregulation of 
C3aR1 in microglia has been found following CNS injury, and our lab has shown that 
C3aR1 is upregulated in lumbar dorsal horn microglia in a time-dependent manner 
following peripheral nerve injury and spinal cord injury. We previously used an 
immunoneutralization approach to demonstrate that TLQP-21 contributes to nerve injury-
induced hypersensitivity (Fairbanks et al., 2014), and in addition we evaluated the effect 
of the C3aR1 antagonist SB290157 in the SNI model of neuropathic pain. The antagonist 
reversed mechanical hypersensitivity as compared to vehicle, but the half-life of the 
C3aR1 antagonist is approximately 1.5 hours, and therefore any effect of reducing 
signaling through C3aR1 could only be assessed acutely. The antagonist has exhibited 
agonist activity in some cells (Mathieu et al., 2005; Therien, Baelder, & Kohl, 2014), and 
it also binds to several nonspecific targets (Proctor et al., 2004), so evaluation of the 
behavioral effects of reducing C3aR1 signaling is difficult to separate from off-target 
effects. Additionally, the only C3aR1 knockout model available is a global knockout, and 
there are potential compensatory mechanisms occurring throughout development. In 
order to assess longer-term effects of reducing signaling through C3aR1 in adult mice, the 
development of antisense oligonucleotides specifically designed to suppress C3aR1 
expression provides a promising avenue for long-term gene knockdown.  
 
Antisense oligonucleotides (ASOs) have been one of the most popular methods utilized 
in scientific research to alter gene expression in vivo over the past 25 years. ASOs are 
synthetically produced short sequences of 13-25 nucleotides in length, designed to 
hybridize to a target mRNA by aligning complementary base pairs. The ASO binding to 
the target mRNA creates a DNA/RNA heteroduplex, and ribonuclease H1 (RNase H) is 
an enzyme that is recruited to degrade these heteroduplexes in both the cytoplasm and 
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nucleus (Dias & Stein, 2002; Kole, Krainer, & Altman, 2012; Koller & Dean, 2006). Once 
the mRNA is degraded, the ASO is released from the target and is free to bind to more 
target mRNA strands, thus one strand of an ASO is able to degrade multiple mRNA 
target strands. Each target mRNA codes for a specific protein, and the ASO binding to 
and promoting the degradation of this mRNA disrupts the synthesis of this particular 
protein. The consequence of ASO administration is selective, efficient, and long-lasting 
knockdown of a target protein.  
 
Antisense oligonucleotides have therapeutic potential (Evers, Toonen, & van Roon-
Mom, 2015), and a number of studies have utilized ASOs to explore knockdown of 
targets involved in nociception. Chronic constriction injury is a model of peripheral nerve 
injury-induced neuropathic pain, and it leads to hypersensitivity in mice. Knockdown of 
NF-kB, a key mediator of immune activation, via ASOs prior to CCI significantly 
attenuated the development of mechanical allodynia and thermal hyperalgesia (T. Sun 
et al., 2006). ASOs have also been utilized in inflammatory pain models, where 
knockdown of the P2X3 receptor has effectively attenuated CFA-induced thermal 
hyperalgesia and hindpaw formalin injection-induced nociceptive behaviors (Honore et 
al., 2002).  
 
Our goal was to examine the consequences of knocking down C3aR1 expression with 
antisense oligonucleotides in the context of peripheral and central models of 
hypersensitivity. These studies are the first to examine the consequence of C3aR1 
knockdown on pain-related behaviors following injury.  
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Methods: 
 
C3aR1 antisense oligonucleotide: Antisense oligonucleotides (ASOs) were developed by 
researchers BF and HK at Ionis Pharmaceuticals. ASOs were designed with five 2’-O-
methoxyethyl-modified ribonucleotides on the 5’ and 3’ ends, and a phosphorothioate 
backbone aimed at promoting uptake and improving nuclease resistance. The middle 
targeting oliognucleotides bound to the complementary base pairs of the target mRNA, 
which recruited RNase H for degradation. The stock solution of ASO was 100 ug/ul, diluted 
in phosphate buffered saline. ASO was diluted 1:2 in 0.9% sterile saline for intrathecal 
injections, where 10ul of diluted ASO was injected over 15-30 seconds. The final 
concentration of ASO injected per subject was 500 ug in 10ul. Vehicle solution for injection 
was a 1:1 mix of phosphate buffered saline and 0.9% sterile saline. Sequence for C3aR1 
ASO: (ACCAAGTTTTCATCCAATTT). Sequence for control non-targeting ASO: 
(CCTATAGGACTATCCAGGAA).  
 
Spared Nerve Injury (SNI) model: The spared nerve injury model is a well-established 
model that produces substantial and prolonged changes in mechanical sensitivity and 
cold responsiveness that closely mimic the cutaneous hypersensitivity associated with 
clinical neuropathic pain (Decosterd & Woolf, 2000). SNI or sham surgery were 
performed under isoflurane anesthesia as described (Bourquin et al., 2006). 
 
Spinal cord injury and postoperative care: All studies were approved by the University of 
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Minnesota Institutional Animal Care and Use Committee (IACUC).  Thoracic spinal cord 
injury or sham surgery was performed on male ICR wild-type mice (Crl:CD1(ICR), Charles 
River, Wilmington, MA, USA) at 5 weeks of age. Prior to surgery, each subject was given 
0.5cc of sterile saline subcutaneously in each hindquarter. Briefly, a laminectomy was 
performed at T9, and the contusion injury was made with either 50 or 75 kdyn of force with 
the IH-0400 Infinite Horizons Impactor (Precision Systems and Instrumentation, LLC; 
Lexington, KY, USA) with a 1.3 mm mouse tip. Sham controls had a laminectomy at T9 
with no impact, and naïve subjects were housed in separate cages at the same time as 
their surgical counterparts. Animals received amoxicillin (14 g/L in drinking water) for 
7 days after surgery to prevent urinary tract infection as part of standard postoperative 
care. Urine was expressed manually twice daily for the first 7 days after surgery and daily 
thereafter until the return of independent urination. Animals were assigned to the following 
groups listed in Table 3.1:  
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Functional assessment: Locomotor recovery following injury was assessed by two 
observers using the Basso Mouse Scale (BMS) (Basso et al., 2006) on days 1, 3, 5, 7, 14, 
21, 28, and 35 days following injury. Briefly, measurements were made on a 9-point scale 
derived from ankle movements, plantar/dorsal hindpaw stepping, coordination, trunk 
instability, and tail position. Mice were placed into an open field and monitored for five 
minutes each, with scores from 0 (complete paralysis) to 9 (normal locomotion) measured 
for each hindpaw. BMS scores were compared between treatments via repeated-
measures analysis of variance. 
  
Behavioral Testing:  
A number of behavioral tests were performed following sham or thoracic spinal cord injury 
beginning at 35 days post-injury and concluding at 45 days. These include:  
 
Rotarod: Mice were tested with the rotarod apparatus (Ugo Basile, Gemonio, Italy). Mice 
were placed on an elevated rotating cylinder that increased in RPM continuously over 300 
seconds, from 5 RPM to a peak of 50 RPM. RPM at fall was recorded for three consecutive 
days, beginning at Day 35 post-surgery. No more than four mice were tested 
simultaneously.  
 
Von Frey mechanical allodynia testing: Mechanical withdrawal thresholds for the hindpaw 
were measured at baseline and on Day 42 post-surgery by an experimenter blind to 
condition. Mice were acclimated at least 30 minutes in the testing environment within a 
glass cup on a raised metal mesh platform. To evaluate mechanical threshold we utilized 
a logarithmically increasing set of 8 von Frey filaments (Stoelting, Wood Dale, IL), ranging 
in gram force from 0.007 to 6.0 g. These were applied perpendicular to the medial hindpaw 
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surface with sufficient force to cause a slight bending of the filament. A positive response 
was characterized as a rapid withdrawal of the paw away from the stimulus fiber within 4 
s. Using the up-down statistical method (Bonin et al., 2014; Chaplan et al., 1994), the 
withdrawal threshold was calculated for each mouse and then averaged within the 
experimental groups.  
 
Hargreaves thermal hyperalgesia testing: Mice were tested for hindpaw thermal 
hyperalgesia using the IITC Plantar Test system at intensity: AI 30 (IITC Life Sciences, 
Woodland Hills, CA). Briefly mice were acclimated to an ambient floor (33°C) and a beam 
of focused light was aimed at each hindpaw. The length of time until paw withdrawal was 
measured. A humane cutoff time was automatically calibrated from the intensity settings.  
 
Burrowing behavior: Burrowing is an ethologically relevant behavior for mice (Robert M.J. 
Deacon, 2006), and others have utilized this as a measure of spontaneous pain following 
injury, which is improved with analgesic administration (Andrews et al., 2012; Deuis et al., 
2017; Jirkof et al., 2010). Briefly, a PVC tube with a cap at one end is elevated on the 
other end and filled with normal chow, and is placed in the home cage of each individually 
housed mouse. The amount of material burrowed during a 2-hour period is weighed, and 
then the remaining material in the tube is weighed. Data shown as (Material 
Burrowed)/(Total Material)*100 to get a burrowing percentage.  
 
Cotton Swab Test: The cotton swab test is a dynamic tactile sensitivity assay designed to 
test light touch sensitivity (Garrison et al., 2011). This test utilizes a cotton swab puffed 
out to 3x its size, and the swab is brushed along the plantar surface five times with a 10-
second break between applications, with the number of paw withdrawals recorded.  
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Cold Allodynia: Acetone was loaded into a 1mL syringe, and a bubble of acetone was 
brought above the tip of the syringe and placed onto the hindpaw without touching the 
syringe to the paw, a total of three times. The average amount of time each subject spent 
lifting, flicking, and licking the paw was recorded and averaged across each application.   
 
 
Results: 
 
We aimed to examine the effects of ASO treatment on hypersensitivity following 
peripheral and central models of neuropathic pain. For the peripheral model, we utilized 
the well-established spared nerve injury model (Decosterd & Woolf, 2000), after which 
the subject has reliable and long-lasting mechanical hypersensitivity arising within a 
week of injury. For the central model, we utilized spinal cord contusion injury at the level 
of the thoracic cord, which is a less established pain model that produces mechanical 
and thermal hypersensitivity in mice in a more variable manner (Hoschouer et al., 2010; 
Kerr & David, 2007; Meisner et al., 2010a). 
 
Assessment of C3aR1 knockdown:  
 
During the optimization process at Ionis Pharmaceuticals, they were able to produce 
reliable knockdown of C3aR1 expression (60% reduction on average) in the lumbar 
spinal cord assessed via qPCR. We confirmed that the C3aR1 ASO in our hands 
successfully knocks down C3aR1 mRNA in the lumbar, thoracic, and cervical spinal 
cord, via qPCR (Fig. 3.1 a-c, qPCR performed by BK).  In both injury models utilized for 
	 74	
these studies, we assessed the knockdown of the receptor via immunohistochemistry. 
Our previous work found expression of C3aR1 primarily localized to microglial profiles in 
the parenchyma, in SNI lumbar spinal cord (Doolen et al., 2017). Additionally, C3aR1 
labeling was intense in the subarachnoid macrophages apposed to the cord, located 
around the entire circumference. Following administration of C3aR1 ASO, we observed 
knockdown of C3aR1 expression in microglia in the lumbar spinal cord (Fig. 3.1 a-b). In 
contrast, there is clearly detectable labeling in the subarachnoid macrophages surround 
the cord, suggesting that there is ineffective knockdown of C3aR1 in these cells. (Fig. 
3.1 d-e).  
 
Figure 3.1: Treatment with C3aR1 ASO significantly knocks down expression of C3aR1 
in the spinal cord. (A-C) Mice received thoracic contusion spinal cord injury, and C3aR1 
ASO or vehicle were injected i.t. on day 70 post-SCI. On day 84 post-SCI, spinal cords  
were removed and separated into lumbar, thoracic, and cervical sections. Naïve age-
matched controls had tissue collected at the same time. C3aR1 mRNA was measured via 
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qPCR by BK at Ionis Pharmaceuticals. A. In the lumbar spinal cord, C3aR1 ASO treated 
mice had reduced C3aR1 expression, which was not significantly different than naïve 
control mice. There was significant knockdown of C3aR1 mRNA in the: B.  thoracic and 
C. cervical spinal cord compared to vehicle controls (p<0.001 and p<0.05 respectively).  
(D-E) Lumbar spinal cord sections of mice that underwent spinal cord injury received i.t. 
injections of C3aR1 ASO or vehicle 3 days after injury. Red = C3aR1 staining D. C3aR1-
ir is localized to microglial profiles in the lumbar dorsal horn of SNI mice. E. C3aR1 ASO 
given at 14 days following injury knocks down C3aR1-ir in microglial profiles in the lumbar 
dorsal horn of SNI mice. Arrows: Subarachnoid macrophages in mice that received 
C3aR1 ASO still express C3aR1-ir at similar levels to vehicle treated mice. Quantification 
of knockdown not performed. 
 
Peripheral Nerve Injury 
 
Treatment with C3aR1 ASO has no effect on the development or maintenance of 
hypersensitivity following peripheral nerve injury 
 
Our aim was to examine the effect of knocking down C3aR1 on development and 
maintenance of SNI-induced hypersensitivity. For the development paradigm, mice 
received C3aR1 ASO or vehicle 7 days before SNI.  They were tested post-injury for 
differences in development of mechanical allodynia. For the maintenance paradigm, 
mice were given C3aR1 ASO or vehicle 14 days after SNI. Von Frey thresholds were 
tested weekly following treatment. In either paradigm, mice that received injection of 
C3aR1 ASO showed no differences in hypersensitivity compared to vehicle controls (Fig 
3.2 a-b; development: p=0.982; maintenance: p=0.749; linear regression analysis for 
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slope and intercept). This indicates that knockdown of C3aR1 expression in microglia 
was not sufficient enough to alter the development or maintenance of hypersensitivity 
following SNI.  
 
 
Fig. 3.2: Treatment with C3aR1 ASO has no effect on the development or maintenance 
of hypersensitivity following peripheral nerve injury. A. Development paradigm: Mice 
received an i.t. Injection of vehicle or C3aR1 ASO 7 days before spared nerve injury, in 
order to ensure sufficient knockdown prior to surgical manipulation. Mice were given an 
SNI, and tested for mechanical allodynia with Von Frey filaments three days after injury. 
There were no significant differences in withdrawal thresholds between vehicle or C3aR1 
ASO treated mice (p=0.982, linear regression analysis for slope and intercept). B. 
Maintenance paradigm: Mice received SNI and were tested with Von Frey filaments  
weekly to ensure development of mechanical allodynia. On 14 days post-surgery, mice 
received i.t. Injections of either vehicle or C3aR1 ASO. Subjects were tested weekly, with 
no significant differences in withdrawal threshold detected at 7 or 14 days following 
treatment. (p=0.749, linear regression analysis for slope and intercept).  
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Spinal Cord Injury  
 
Spinal cord injury is a central nervous system injury capable of producing 
hypersensitivity in mouse and rat models. First, we aimed to examine whether C3aR1 
expression is increased following SCI in a similar manner as SNI. We then sought to 
determine whether treatment with C3aR1 ASO altered the development of injury-related 
behaviors following SCI. For these experiments, we utilized both a mild and a moderate 
contusion injury. This was to assess whether severity of injury influenced the 
effectiveness of C3aR1 knockdown on behavior.  
 
Spinal cord injury increases the spinal expression of C3aR1 in a time-dependent 
manner: 
 
Our work utilizing spared nerve injury found time-dependent upregulation of C3aR1 
specifically in microglia following peripheral nerve injury (Doolen et al., 2017). Following 
our work characterizing microglial C3aR1 expression at various timepoints after 
peripheral nerve injury, we aimed to examine whether changes in C3aR1 expression 
occur following spinal cord injury.  
 
The contusion injury at the level of T9 elicited a mild injury that mice recover from in a 
stereotypical fashion, and we assessed C3aR1 expression below the level of injury at 
both the acute and chronic stage. In addition to assessing C3aR1 expression, we also 
aimed to characterize changes in microglial marker expression by assessing Iba1 
immunoreactivity on the same sections.  We compared the SCI subjects to the sham 
controls in order to control for changes in C3aR1 or Iba1 expression due primarily to the 
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laminectomy. We found time-dependent changes in C3aR1 and Iba1 expression at both 
the acute and the chronic timepoints after SCI in comparison to sham controls. At six 
days post-surgery, we saw a significant increase in both C3aR1-ir and Iba1-ir in the 
lumbar dorsal horn of SCI subjects in comparison to sham controls (Fig. 3.3a1-d1; p= 
0.0098, p=0.0046 respectively, unpaired t-test). At fifty days post-surgery, when the 
subjects are recovered from the acute effects of the injury and have resumed normal 
locomotion, Iba1 was still significantly increased in SCI mice (Fig. 3.3a2-d2; p=0.032, 
unpaired t-test), whereas C3aR1 was not significantly different in SCI subjects compared 
to sham controls (p=0.280, unpaired t-test).  
 
 
Figure 3.3: Spinal expression of C3aR1 and Iba1 is increased 6 days after spinal cord 
injury. (a1-b1) Representative images illustrate the increase in C3aR1-ir and Iba1-ir at 
day 6 post-SCI (A1, sham; B1, SCI). Scale bar: 100 μm.  (c2-d2) Quantitative analysis 
of C3aR1 and Iba1 immunolabeling indicates a significant increase in C3aR1 expression 
and Iba1 expression occurs 6 days post-SCI (p= 0.0098, p=0.0046 respectively, 
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unpaired t-test). (a2-b2) Representative images illustrate the increase in Iba1-ir at day 
50 post-SCI, whereas C3aR1-ir is equally low in sham and SCI. (A, sham; B, SCI) Scale 
bar: 100 μm. (c2-d2) Quantitative analysis of C3aR1 and Iba1 immunolabeling indicates 
a significant increase in Iba1 expression, that is not present in C3ar1, at 50 days post-
SCI (p=0.032 and p=0.280 respectively, unpaired t-test).  
 
 
 
We next aimed to identify changes occurring rostral to the injury, specifically in the 
gracile fasciculus portion of the dorsal columns. We stained for C3aR1 and Iba1 on 
cervical sections, and imaged the dorsomedial portion of the spinal cord. We visualized 
C3aR1-ir and Iba1-ir in the dorsal columns of mice that received spinal cord injury (Fig. 
3.4a-c: a: C3aR1-ir (red) and Iba1-ir (green); b: Iba1-ir (white); c: C3aR1-ir (white); Scale 
bar 100 𝜇𝑚). This indicates that following SCI, long-lasting immune activation occurs in 
the dorsal columns. Quantification of Iba1 and C3aR1 are in process.  
 
 
Figure 3.4: Iba1 and C3aR1 are present in the dorsal columns of SCI mice. 
Immunohistochemistry examining C3aR1 and Iba1 in the dorsomedial cervical spinal 
cord. a: Representative images of co-labeling of C3aR1-ir (red) and Iba1-ir (green) in the 
gracile fasciculus of SCI subjects at 45 days following injury. b: Iba1-ir and c: C3aR1-ir 
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in dorsomedial cervical spinal cord of SCI mice. Scale bar: 100𝜇𝑚. 
 
 
 
 
 
Treatment with C3aR1 ASO 3 days following a mild 50 kdyn thoracic contusion 
SCI has variable effect on behavior in male ICR mice: 
 
Following intrathecal injection of C3aR1 ASO or vehicle at 3 days following a mild 50 
kdyn thoracic contusion SCI, a number of behaviors were monitored. We chose day 
three following injury in order to knock down receptor expression during the acute phase 
of injury, which is when we found peak C3aR1 expression. Administering the treatment 
during the acute phase of injury allowed us to examine the effects of knockdown on 
development of pain-related behavior. BMS scoring was done on days 1, 3, 5, 7, and 
then weekly after injury in order to assess locomotor function. Following mild or moderate 
injury, mice recover locomotor function in a stereotypical fashion, from low day one 
scores to a plateau occurring between 28 and 35 days post-SCI. On day one after injury, 
there are a percentage of each cohort that have scores of 4 or higher, indicating a less 
severe injury. Results are presented in several ways, in one graph combining all subjects 
for each group, and in another splitting subjects based on their BMS scores on day one 
post-injury. This was to examine whether there were trends in ASO effects on behavior 
that were dependent on injury severity. Additionally, we ran Pearson’s correlations 
comparing behavior to BMS scores on day one, to examine the relationships between 
these variables. There were no significant differences between the locomotor recovery 
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of subjects that received C3aR1 ASO compared to the vehicle controls, in either the 
combined or separated analyses. (Fig. 3.5a1-2; combined: p=0.972, low day one: 
p=0.275, high day one: p=0.709;  mixed effects model with Sidak’s multiple comparisons 
test).  This indicates the ASO does not impact locomotor recovery following a mild 50 
kdyn thoracic contusion injury.  
 
 
We utilized a number of evoked and spontaneous behavioral tests in order to assess the 
effects of C3aR1 knockdown on pain-related behaviors.  
 
We assessed the impact of ASO-mediated knockdown of C3aR1 expression on 
mechanical sensitivity. When high and low day one BMS groups were combined, the 
sham that received vehicle had significantly lower withdrawal thresholds than both SCI 
vehicle and SCI ASO groups (Fig. 3.5b1; p=0.0191, one-way ANOVA with Tukey’s post 
hoc). Interestingly, sham that received ASO were not significantly different than either 
SCI group. When low and high day one BMS groups were separated, the sham vehicle 
were significantly lower than both the vehicle and ASO SCI groups that had low day one 
BMS scores (Fig. 3.5b2; p=0.0096, one-way ANOVA with Tukey’s post hoc). When we 
ran correlations comparing day one BMS scores to withdrawal threshold, both the 
vehicle and ASO SCI groups exhibited a negative correlation between BMS day one 
score and withdrawal thresholds. These were not significantly different from one another 
(Fig. 3.5b3; vehicle: r=0.411; C3aR1 ASO: r=0.656).   
 
Burrowing is an ethologically relevant behavior in mice, most frequently utilized as a 
model of overall well-being (R. M.J. Deacon, 2009; Robert M.J. Deacon, 2006; Jirkof, 
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2014). Some have used this as a measure of spontaneous pain following injury, which 
is improved with analgesic administration (Andrews et al., 2012; Deuis et al., 2017; Jirkof 
et al., 2010). When we tested the effects of ASO on burrowing behavior, there were no 
significant differences between any group, regardless of surgical group or treatment (Fig. 
3.5c1; p = 0.4356, one way anova with Tukey’s post hoc). This remained true when SCI 
subjecst were split into groups based on day one BMS scores (Fig. 3.5c2; p=0.074, one-
way ANOVA with Tukey’s post hoc). We ran correlations comparing the relationship 
between burrowing and injury severity on day one post-SCI, and both vehicle and ASO 
groups had positive correlations that were not different from one another (Fig. 3.5c3; 
vehicle: r=0.800; C3aR1 ASO: r=0.746).  
 
We assessed heat hyperalgesia with the Hargreaves apparatus, which utilizes a radiant 
heat source aimed toward the hindpaw. Subjects with heat hyperalgesia will exhibit 
reduced latency to withdraw from the light (Deuis et al., 2017; Hargreaves et al., 1988). 
When we tested the effects of the C3aR1 ASO on withdrawal latency, there were no 
significant differences between any group, regardless of surgical group or treatment (Fig. 
3.5d1; p=0.702, one-way ANOVA with Tukey’s post hoc). This remained true when SCI 
subjects were split into groups based on day one BMS scores (Fig. 3.5d2; p=0.316, one-
way ANOVA with Tukey’s post hoc). We ran correlations comparing the relationship 
between withdrawal latency and injury severity on day one post-SCI, and both vehicle 
and ASO groups had positive correlations that were not different from one another (Fig. 
3.5d3; vehicle: r=0.711; C3aR1 ASO: r=0.468).  
 
The cotton swab test is used to examine light touch sensitivity, specifically testing the 
presence of information being sent from low-threshold rapidly adapting 
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mechanoreceptors. When low and high day one BMS groups are combined, both the 
vehicle and C3aR1 ASO spinal cord injury groups have significantly reduced responses 
to the cotton swab stimulus compared to the naïve or either sham group. (Fig. 3.5f; 
p=0.0013, one way anova; tukeys post hoc test).  When subjects are separated based 
on their day one BMS score, a noteworthy trend emerges. The vehicle SCI group is still 
reduced compared to the sham or naïve mice, regardless of injury severity. For SCI mice 
that received ASO, the more injured group on day one is also reduced compared to 
naïve or sham groups. Interestingly, the SCI mice with high day one BMS scores that 
received C3aR1 ASO respond to the cotton swab stimulus. They have significantly 
higher response percentages than the SCI vehicle or low day one ASO group, and are 
not significantly different than the naïve or sham groups (Fig. 3.5e2; p<0.0001; one-way 
ANOVA with Tukey’s post hoc). This indicates that the C3aR1 ASO is capable of 
attenuating the loss of light touch sensitivity in mice that are less injured on day one post-
SCI. We ran correlations comparing day one BMS score and percent response to the 
cotton swab stimulus. In line with the changes seen in the raw data, the relationship 
between injury severity and cotton swab response are significantly different between 
vehicle and C3aR1 ASO treatments. There is a slightly negative but nearly absent 
correlation between injury severity and response to the cotton swab for the SCI mice 
that received vehicle, indicating that there is no relationship between injury severity and 
whether the mice will respond to the stimulus (Fig. 3.5e3; r = -0.099). In contrast, there 
is a highly positive correlation between injury severity and percent response in the SCI 
mice that receive C3aR1 ASO, indicating that less injured mice on day one are more 
likely to have higher responses to the cotton swab (Fig. 3.5e3; r = 0.931).  
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Figure 3.5: Treatment with C3aR1 ASO 3 days following a mild 50 kdyn contusion SCI 
has variable effect on pain-related behaviors. A1-2. BMS locomotor scoring was done 
on days 1, 3, 5, 7, and then weekly through 28 days. Mice that received C3aR1 ASO 
recovered locomotor function in a similar manner as vehicle control subjects, regardless 
of whether high and low day one BMS scores were combined or separated (p=0.555 and 
	 85	
p=0.641, mixed effects model with Tukeys post hoc). B1.  When high and low day one 
BMS groups were combined, the sham that received vehicle had significantly lower 
withdrawal thresholds than both SCI vehicle and SCI ASO groups ( p=0.0191, one-way 
ANOVA with Tukey’s post hoc). B2. When low and high day one BMS groups were 
separated, the sham vehicle were significantly lower than both the vehicle and ASO SCI 
groups that had low day one BMS scores (p=0.0096, one-way ANOVA with Tukey’s post 
hoc). C1-2.  When we tested the effects of ASO on burrowing behavior, there were no 
significant differences between any group, regardless of surgical group or treatment (Fig. 
3.5c1; p = 0.4356, one way anova with Tukey’s post hoc). This remained true when SCI 
subjecst were split into groups based on day one BMS scores (p=0.074, one-way 
ANOVA with Tukey’s post hoc). D1-2. When we tested the effects of the C3aR1 ASO on 
withdrawal latency, there were no significant differences between any group, regardless 
of surgical group or treatment (p=0.702, one-way ANOVA with Tukey’s post hoc). This 
remained true when SCI subjects were split into groups based on day one BMS scores 
(p=0.316, one-way ANOVA with Tukey’s post hoc). D3. We ran correlations comparing 
the relationship between withdrawal latency and injury severity on day one post-SCI, 
and both vehicle and ASO groups had positive correlations that were not different from 
one another (vehicle: r=0.711; C3aR1 ASO: r=0.468). E1. When low and high day one 
BMS groups are combined, both the vehicle and C3aR1 ASO spinal cord injury groups 
have significantly reduced responses to the cotton swab stimulus compared to the naïve 
or either sham group. (p=0.0013, one way anova; tukeys post hoc test).  E2. When 
subjects are separated based on their day one BMS score, the vehicle SCI group is still 
reduced compared to the sham or naïve mice, regardless of injury severity. For SCI mice 
that received ASO, the more injured group on day one is also reduced compared to 
naïve or sham groups. The SCI mice with high day one BMS scores that received C3aR1 
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ASO have significantly higher response percentages than the SCI vehicle or low day 
one ASO group, and are not significantly different than the naïve or sham groups 
(p<0.0001; one-way ANOVA with Tukey’s post hoc). 
 
 
 
 
Treatment with C3aR1 ASO 3 days following moderate 75 kdyn thoracic contusion 
SCI has a variable effect on behavior in male ICR mice: 
  
We aimed to compare effects of C3aR1 ASO treatment on improvement of pain-related 
behaviors between mild and moderate spinal cord injury. To do this we tested a number 
of evoked and spontaneous behaviors in mice that received a moderate 75 kdyn thoracic 
contusion SCI. BMS scoring was assessed on day 1, 3, 5, 7, and then weekly through 
35 days following moderate contusion SCI. There were no significant differences 
between the locomotor recovery of subjects that received C3aR1 ASO compared to the 
vehicle controls. (Fig. 3.6a0; p=0.841, two-way ANOVA with Tukey’s post hoc).  There 
were not enough mice with high day one scores to meaningfully test the differences 
between groups that had low or high day one BMS scores. Therefore, we combined all 
subjects and compared the effect of C3aR1 ASO treatment on the behaviors we tested. 
There were no significant differences in direct comparison of values for Von Frey 
mechanical thresholds (Fig. 3.6a1; p=0.849, one-way ANOVA, Tukey’s post hoc), 
burrowing percentage (Fig. 3.6b1; p=0.182, one-way ANOVA, Tukey’s post hoc), or 
thermal withdrawal latencies (Fig. 3.6c1; p=0.5309, One way ANOVA, Tukey’s post hoc) 
between any of the groups. In the cotton swab test, we saw a significant decrease of 
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SCI responses in comparison to naïve controls, regardless of treatment group (Fig. 
3.6d1; p = 0.0015, one way ANOVA, Tukey’s post hoc), but there was no effect of C3aR1 
ASO on percent responses compared to SCI mice that received vehicle. When we ran 
correlations comparing BMS scores on day one with each behavior that we tested, there 
were differences that emerged between vehicle and C3aR1 ASO groups for the 
Hargreaves assay and the cotton swab test. In the Hargreaves assay, the vehicle group 
had a highly positive correlation between BMS scores on day one and withdrawal 
latency, with less severely injured mice having higher withdrawal latencies than more 
injured subjects (Fig. 3.5c2; vehicle: r = 0.992). For the C3aR1 ASO group, there was a 
negative correlation between BMS score and withdrawal latency, indicating that less 
injured mice were more likely to have lower withdrawal latencies than their more injured 
counterparts (Fig. 3.5c2; C3aR1 ASO: r = -0.711). In the cotton swab test, the vehicle 
group had a slightly negative but overall insignificant correlation between BMS scores 
on day one and percent response, indicating that there was no impact of injury severity 
on response (Fig. 3.5d2; vehicle: r = -0.284). For the C3aR1 ASO group, there was a 
highly positive correlation between BMS score and percent response, indicating that less 
injured mice were more likely to respond to the cotton swab stimulus than their more 
injured counterparts (Fig. 2.5d2; C3aR1 ASO: r = 0.957). These results are in line with 
our findings in the mild 50 kdyn injuries, where the C3aR1 ASO attenuated the loss of 
light touch sensitivity compared to the low BMS group and the vehicle controls.  
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Figure 3.6: Treatment with C3aR1 ASO 3 days following moderate 75 kdyn thoracic 
contusion SCI has a variable effect on behavior in male ICR mice: A0. There were no 
significant differences between the locomotor recovery of subjects that received C3aR1 
ASO compared to the vehicle controls. (Fig. 3.6a0; p=0.841, two-way ANOVA with 
Tukey’s post hoc). A1-C1. There were no significant differences in direct comparison of 
values for Von Frey mechanical thresholds (Fig. 3.6a1; p=0.849, one-way ANOVA, 
Tukey’s post hoc), burrowing percentage (Fig. 3.6b1; p=0.182, one-way ANOVA, 
Tukey’s post hoc), or thermal withdrawal latencies (Fig. 3.6c1; p=0.5309, One way 
ANOVA, Tukey’s post hoc) between any of the groups. D1. In the cotton swab test, we 
saw a significant decrease of SCI responses in comparison to naïve controls, regardless 
of treatment group (Fig. 3.6d1; p = 0.0015, one way ANOVA, Tukey’s post hoc), but 
there was no effect of C3aR1 ASO on percent responses compared to SCI mice that 
received vehicle. A2-D2. Correlations were comparing BMS scores on day one with each 
behavior that we tested, to assess differences between vehicle and C3aR1 ASO groups. 
R-values are reported in the figure.  
 
 
 
Control ASO induces upregulation of C3aR1 expression and thermal 
hypersensitivity in injured subjects: 
It was important for us to test whether the ASO itself had non-specific effects that were 
measurable following spinal cord injury. In order to do so, we utilized a control ASO that 
had a sequence of nucleotides with no known target in mice or rats. We injected vehicle, 
control ASO, or C3aR1 ASO in SCI mice at day 3 post-injury. We then assessed a 
number of evoked and spontaneous behaviors. At 45 days post-injury, we collected 
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tissue and quantified changes in C3aR1 and Iba1 expression in the lumbar dorsal horn. 
When subjects were combined regardless of day one BMS score, there were no 
significant differences in BMS scores, von frey withdrawal thresholds, burrowing 
percentages, or responses to cotton swab when comparing vehicle, control ASO, or 
C3aR1 ASO groups (Fig. 3.7a1-c1,e1; BMS: p=0.555, two-way ANOVA with Sidak’s 
multiple comparisons test; Von Frey: p=0.467, one-way ANOVA with Tukey’s post hoc; 
Burrowing: p=0.248, one-way ANOVA with Tukey’s post hoc; cotton swab: p=0.905, one-
way ANOVA with Tukey’s post hoc). This remained true when day one BMS groups were 
separated, even though each treatment had higher percent responses to the cotton swab 
stimulus in their high day one BMS group (Fig. 3.7a2-c2,e2; von frey: p=0.156, one-way 
ANOVA; burrowing: p=0.162, one-way ANOVA; cotton swab: p<0.0001, one-way 
ANOVA with Tukey’s post hoc). When low and high day one BMS groups are combined, 
the control ASO group had significantly reduced withdrawal latency in the Hargreaves 
thermal hyperalgesia assay when compared to both the vehicle and C3aR1 ASO groups, 
and the naïve controls (Fig 3.7c; p=0.0061, one-way ANOVA with tukey’s post hoc). 
When subjects with low or high day one BMS scores are separated, the low day one 
group that received control ASO had significantly reduced thresholds compared to naïve, 
high day one vehicle, and low day one C3aR1 ASO groups (Fig. 3.7e2; p = 0.0056, one-
way ANOVA with Tukey’s post hoc). These results indicate that control ASO is capable 
of eliciting thermal hyperalgesia, which is more likely to occur in the mice that are more 
injured on day one post-SCI. Comparisons in the correlation of day one BMS score to 
the various behaviors did not reveal any significant differences between vehicle and 
control ASO (Fig. 3.7b3-e3; r values reported in figure). For the burrowing task, the 
vehicle and control ASO groups had positive correlations between injury severity on day 
one and burrowing. The C3aR1 ASO group had no correlation between burrowing 
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percentage and injury severity. (Fig. 3.7c; vehicle: r = 0.995; control ASO: r = 0.861; 
C3aR1 ASO: r = -0.170).  
 
 
Figure 3.7: Control ASO induces thermal hypersensitivity in injured subjects. A1. BMS 
locomotor scoring was done on days 1, 3, 5,7, and then weekly through 35 days. Mice 
	 92	
that received control ASO recovered locomotor function the same as vehicle control and 
C3aR1 ASO subjects (p=0.555, two-way ANOVA). B1. Burrowing was assessed on day 
35-36 post-SCI, and there were no significant differences between control ASO, C3aR1 
ASO, and vehicle subjects (p=0.248, one-way ANOVA). C1. The control ASO group had 
significantly reduced withdrawal latency in the Hargreaves thermal hyperalgesia assay 
when compared to both the vehicle and C3aR1 ASO groups, and the naïve controls 
(p=0.0061, one-way ANOVA with tukey’s post hoc) D1. There were no significant 
differences in von frey thresholds between groups (p=0.467, one-way ANOVA, tukey’s 
post hoc). E1. All injured mice exhibited reduced responsiveness in the cotton swab 
assay. There were no differences between vehicle, control ASO, or C3aR1 ASO subjects 
(p=0.905, one-way ANOVA, tukey’s post hoc) A2-C2,E2:  These trends remained true 
when day one BMS groups were separated, even though each treatment had higher 
percent responses to the cotton swab stimulus in their high day one BMS group (Fig. 
3.7a2-c2,e2; von frey: p=0.156, one-way ANOVA; burrowing: p=0.162, one-way 
ANOVA; cotton swab: p<0.0001, one-way ANOVA with Tukey’s post hoc). D2. When 
subjects with low or high day one BMS scores are separated, the low day one group that 
received control ASO had significantly reduced thresholds compared to naïve, high day 
one vehicle, and low day one C3aR1 ASO groups (Fig. 3.7e2; p = 0.0056, one-way 
ANOVA with Tukey’s post hoc). B3-E3. Comparisons in the correlation of day one BMS 
score to the various behaviors did not reveal any significant differences between vehicle 
and control ASO (Fig. 3.7b3-e3; r values reported in figure). 
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We collected tissue at 45 days post-SCI and did immunohistochemistry on lumbar spinal 
cord sections. We specifically quantified C3aR1 and Iba1 expression and compared 
each treatment group. We saw a significant increase in C3aR1-ir in control ASO subjects 
in comparison to naïve, SCI vehicle, and SCI C3aR1 ASO mice (Fig. 3.8a; p<0.0001, 
one way ANOVA with tukey’s post hoc). There were no changes in Iba1-ir in control ASO 
compared to any of the other groups (Fig. 3.8b; p=0.117, one-way ANOVA with tukey’s 
post hoc).  
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Figure 3.8: Control ASO-induced changes in expression of C3aR1 in injured subjects. 
A. Quantification of C3aR1-ir and Iba1-ir in the lumbar dorsal horn. Control ASO induces 
significant upregulation in spinal cord injury subjects compared to naïve subjects, and 
SCI subjects that received vehicle or C3aR1 ASO (p<0.0001, one way ANOVA with 
tukey’s post hoc). B. There were no significant differences in Iba1-ir between any 
treatment group (; p=0.117, one-way ANOVA with tukey’s post hoc). (C-E) 
Immunohistochemistry staining in the lumbar dorsal horn of SCI mice that were treated 
*	
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with vehicle, control ASO, or C3aR1 ASO. Red =C3aR1, Green =Iba1, 20x.  
  
 
 
Discussion 
 
In these studies, we sought to determine the effect of ASO-mediated knockdown of 
C3aR1 expression in a peripheral and central model of neuropathic pain. We utilized a 
number of evoked and spontaneous pain-related behaviors, in addition to 
immunohistochemistry, in order to examine these effects.   
 
Effective knockdown of C3aR1 expression with antisense oligonucleotides 
 
Prior to our experiments, the C3aR1 ASO was optimized at Ionis Pharmaceuticals, 
including in vivo examination of gene knockdown in the spinal cord following intrathecal 
injection (data not shown). In order to assess effectiveness of the C3aR1 ASO in our 
hands, we collected tissue at two weeks following administration. Naïve mice have low 
endogenous expression of C3aR1, so we tested the efficiency of the ASO in mice that 
had spinal cord injuries. We confirmed through qPCR (performed by BK) that C3aR1 
was knocked down in the lumbar, thoracic, and cervical sections of the spinal cord. We 
performed immunohistochemistry to assess C3aR1 and Iba1 expression following SNI 
and SCI. We found that C3aR1-ir is knocked down in parenchymal microglia in both 
models. This knockdown of C3aR1 does not seem to affect the presence of Iba1-ir, 
suggesting that there are not any nonspecific effects on microglia. In contrast, there was 
clearly detectable C3aR1 labeling in the subarachnoid macrophages that surround the 
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spinal cord, suggesting that there is ineffective knockdown of C3aR1 in these cells. This 
is most likely due in part to the exceptionally high expression level of C3aR1 in 
subarachnoid macrophages in comparison to microglia. In addition, these cells are 
abundant around the entire circumference of the spinal cord. Both of these factors make 
effective knockdown harder to achieve. These cells are an important consideration when 
assessing the efficacy of the knockdown capability of this particular ASO, which has a 
60% knockdown efficiency, measured by Ionis during the optimization process. Based 
on the near complete knockdown of C3aR1 in the parenchyma seen via 
immunohistochemistry, it is possible that the remaining 40% of C3aR1 expression 
detected in the spinal cord is from subarachnoid macrophages that remain attached to 
the spinal cord tissue assessed via qPCR. It is currently unknown what the functional 
relevance of these cells are in pain-related behavior. Therefore we do not know the 
contribution of these cells to the behavioral phenotypes we examined following C3aR1 
ASO in these models.   
 
C3aR1 ASO is ineffective at disrupting the development or maintenance of mechanical 
hypersensitivity following peripheral nerve injury 
  
In our previous work utilizing the C3aR1 antagonist SB290157, we saw a transient 
attenuation of the maintenance of mechanical allodynia following peripheral nerve injury 
for approximately two hours post intrathecal or intraperitoneal injection. In contrast, C3aR1 
ASO administration either before peripheral nerve injury or after the establishment of 
mechanical allodynia was unable to disrupt the development or maintenance of 
hypersensitivity.  There are a few potential reasons that the antagonist might be working 
more effectively than the C3aR1 ASO at disrupting pain-related behaviors. Firstly, the 
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antagonist is known to have a number of off-target effects that might be disrupting other 
inflammatory mediators to attenuate hypersensitivity (Proctor et al., 2004). Additionally, 
the antagonist is likely binding to and antagonizing C3aR1 located on subarachnoid 
macrophages. These cells still have C3aR1 expression following C3aR1 ASO, therefore 
their activity might be a contributing factor to the remaining pain behavior seen in these 
mice.  
 
Spinal cord injury in male mice increases C3aR1 expression in a time-dependent manner 
Our work in SNI found time-dependent upregulation of C3aR1 specifically in microglia 
following peripheral nerve injury (Doolen et al., 2017). We aimed to examine whether 
changes in microglial C3aR1 expression in the spinal cord occur following SCI, a central 
model of neuropathic pain. Notably, C3aR1 upregulation has been reported after SCI 
(Chen et al., 2013).   It was important for us to examine expression levels after injury prior 
to assessing the effects of C3aR1 knockdown on pain-related behavior after SCI. 
Following SCI, microglia at the injury site are rapidly activated and produce various pro-
inflammatory signaling mediators (David & Kroner, 2011; Huang et al., 2013; Pineau, Sun, 
Bastien, & Lacroix, 2010). Activated microglia appear to contribute to SCI-induced chronic 
pain, since microglial inhibitor treatment or microglial depletion reverses this pain 
phenotype (Hains, 2006b; Zhao, Waxman, & Hains, 2007b). Our results indicate a robust 
and early upregulation of C3aR1 specifically in microglia following spinal cord injury. This 
increase in microglial C3aR1 was highest during the acute phases of injury, steadily 
decreasing over time. These results point to a potentially important role in signaling 
through C3aR1 immediately following injury. The increase in C3aR1 expression we 
visualized occurred as many as 8-9 spinal cord sections below injury, which indicates 
widespread neuroinflammation throughout the length of the spinal cord following thoracic 
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injury. At 50 days following spinal cord injury, the expression of C3aR1 had returned to 
sham levels, whereas the marker for microglia remained elevated. This indicates that 
neuroinflammation may persist throughout the chronic phase of injury, through 
mechanisms other than complement activation. Previous work has shown that decreasing 
components of the alternative complement system, such as Factor B or C3, prior to spinal 
cord injury was associated with increased tissue sparing, decreased inflammatory cell 
infiltration, and improvement in functional recovery (Qiao et al., 2010, 2006). Our findings 
in light of the existing literature led us to conclude that any intervention we tried should 
occur during the acute phase of injury, preferably as close to the date of injury as was 
feasible.  
 
In chapter two, we examined sensory changes that occur following spinal cord injury. 
Using the cotton swab assay, we found a dramatic loss of light touch sensitivity. This 
was most likely mediated through a conduction block of low threshold 
mechanoreceptors, due to damage in the dorsal columns. In addition to examining 
C3aR1 and Iba1 expression below the level of injury, we also looked at cervical sections 
to assess changes in receptor expression occurring in the dorsal columns. We visualized 
C3aR1-ir and Iba1-ir in the gracile fasciculus of the cervical spinal cord of SCI mice. 
Following spinal cord injury, damage to the dorsal portion of the cord causes axonal 
degeneration in the dorsal columns (James et al., 2011). Following the induction of 
demyelination, there is rapid and robust accumulation of activated microglia and 
macrophages at the site of the injured axons (Cao & He, 2013; Hiremath et al., 1998; 
Remington, Babcock, Zehntner, & Owens, 2007). These microglia are responsible for 
clearing debris, to remove damaged tissue and aide in remyelination (Glezer, Simard, & 
Rivest, 2007; Lampron et al., 2015). The robust and long-lasting immune activation 
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occurring in the gracile fasciculus is a potential contributor to the altered sensitivity we 
see in our SCI mice.   
 
 
Treatment with C3aR1 ASO 3 days following a mild or moderate thoracic contusion SCI 
does not impact development of pain-related behavior in male ICR mice: 
 
For our intervention during an acute timepoint following SCI, we did not see any changes 
in evoked or spontaneous measures of pain-related behavior. We assessed mechanical 
sensitivity with von frey filaments, thermal hyperalgesia with the Hargreaves apparatus, 
and spontaneous pain/wellness with the burrowing assay. There is inherent variability in 
whether SCI leads to pain-related behavior following SCI in mice. Our work covered in 
chapter two found that injury severity influences the development of many of these pain-
related behaviors. When we ran correlations comparing injury severity to behavior, there 
were differences in Hargreaves latency between SCI mice treated with C3aR1 ASO 
compared to the vehicle control, but only in the moderate 75 kdyn cohort. Overall, we did 
not find a significant impact of the C3aR1 ASO on pain-related behaviors after SCI. The 
variability in injury severity and whether mice develop hypersensitivity following SCI should 
be kept in mind as a potential complication to effectively assessing the efficacy of the ASO.    
 
 
Spinal cord injury induces a loss of light touch sensitivity that is partially attenuated by 
administration of C3aR1 ASO during the acute phase of injury 
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In mice and rats, contusion spinal cord injury leads to a lesion in the spinal cord that 
encompasses the dorsal columns at the level of injury (Attwell et al., 2018; James et al., 
2011). This disrupts the flow of touch information being sent from the periphery, which we 
have detected in our SCI mice. When comparing responses in mice that received vehicle 
or C3aR1 ASO, we found that the vehicle group had significantly lower thresholds than 
naïve mice, sham vehicle mice, and sham that received C3aR1 ASO. SCI mice that 
received C3aR1 ASO have higher response percentages than their vehicle counterparts, 
but it wasn’t until we separated out subjects high and low day one BMS scores that we 
found a significant effect. The C3aR1 antisense significantly attenuated the loss of light 
touch sensitivity specifically in the mice that were less injured on day one. When we 
correlated injury severity to cotton swab responses, we found in both the mild and 
moderate cohorts, that SCI mice that receive vehicle have no correlation between injury 
severity and whether they respond to the stimulus. This is in contrast to the C3aR1 ASO 
group, which has a highly positive correlation between injury severity and percent 
response, indicating that less injured mice were more likely to respond to the cotton swab 
stimulus compared to their more injured counterparts.  
 
Electrophysiological recordings from teased dorsal root fibers found that following SCI, 
rats have a complete conduction block in ascending dorsal column axons during the acute 
phases of injury (James et al., 2011). Conduction across the lesion improves slightly over 
time, but still remains significantly reduced during the chronic phase of injury. Interestingly, 
though there were still a large number of demyelinated fibers in the dorsal columns during 
the chronic phase, there was a subpopulation of axons that remained myelinated but were 
unable to conduct action potentials (James et al., 2011). As a whole, our results point to 
a potentially protective role of knocking down the C3aR1 receptor in the context of spinal 
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cord injury, specifically in mice that are less severely injured, but further examination of 
this is necessary.  
 
 
Non-targeting Control ASO induces thermal hyperalgesia and C3aR1 upregulation 
following SCI 
 
In order to examine potential target-independent effects of the ASO, we utilized a control 
ASO that has no known target in mice. Our results point to potential immune activation 
elicited by the control ASO, which is capable of causing thermal hypersensitivity and 
dramatic increases in C3aR1 expression. These changes were long-lasting, still present 
at six weeks post-ASO treatment.  Unpublished work from Ionis Pharmaceuticals has 
found that there are some control ASOs that are capable of increasing the amount of C3 
mRNA, the precursor to C3a, one of the ligands for C3aR1 (unpublished, data not 
shown). Though there was not an increase of Iba1 expression in the lumbar cord of the 
control ASO subjects, it is still likely that the increase in C3aR1 was due to immune 
activation. Iba1 stands for ionized calcium binding adaptor molecule 1 (Ito et al., 1998), 
and in mammalian cells it is an actin-binding protein expressed in microglia and 
macrophages (Sasaki, Ohsawa, Kanazawa, Kohsaka, & Imai, 2001). Iba1 enhances 
membrane ruffling and Rac signaling, is involved in phagocytosis, and can enhance 
lymphocyte migration (Ohsawa, Imai, Kanazawa, Sasaki, & Kohsaka, 2000). C3aR1 is 
chiefly located on microglia and macrophages, the immune cells of the spinal cord and 
surrounding tissues. Activation of C3aR1 by it’s ligand elicits calcium transients in 
microglia, and following injury the receptor is specifically upregulated in immune cells 
(Doolen et al., 2017). These findings point to the importance of choosing control ASOs 
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that do not elicit immune activation, and additionally uncovers that C3aR1 is a potentially 
useful marker to examine for whether an ASO elicits an immune response.   
 
In summary, we show that the C3aR1 ASO developed by Ionis Pharmaceuticals effectively 
knocks down expression of C3aR1, at both the mRNA and protein level. The knockdown 
of C3aR1 is near-complete in microglia in the parenchyma of the spinal cord, but is less 
robust in subarachnoid macrophages apposed to the spinal cord. Knocking down C3aR1 
expression did not alter the development or maintenance of hypersensitivity behaviors in 
either injury model. There were promising results pointing to a potentially protective effect 
of knocking down the C3aR1 receptor during the acute phase of spinal cord injury. We 
found that knockdown attenuated the loss of light touch sensitivity seen in spinal cord 
injury animals. Lastly our findings utilizing the control ASO point to C3aR1 as a potentially 
important marker to screen for when assessing whether an ASO causes immune 
activation.  
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OVERALL DISCUSSION 
 
 
Summary of Findings 
 
The research in this dissertation is the first to examine the involvement of the complement-
3a receptor (C3aR1) in peripheral and central neuropathic pain. In chapter one, it was 
found that microglial C3aR1 is upregulated following peripheral injury, and the receptor is 
involved in hypersensitivity partially mediated by the neuropeptide TLQP-21. Chapter two 
presented the most thorough characterization of sensory changes that occur following 
spinal cord injury in male mice to date. For the first time, it was found that spinal cord injury 
induces a loss of light-touch sensitivity in male mice, whereas pain behavior was 
influenced by injury severity. In chapter three, a novel antisense oligonucleotide was used 
to knock down C3aR1 expression in peripheral nerve injury and spinal cord injury. The 
C3aR1 ASO had variable results, but had a potentially protective role in spinal cord injury. 
Additionally, it was found that C3aR1 is a marker that should be examined in future 
screens for ASO-mediated neuroinflammation. This work highlights the potential 
relevance of C3aR1 as a therapeutic target following injury, and uncovers the complex 
role complement receptor-mediated immune signaling has in neuropathic pain.  
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Significance 
 
The work from this thesis fits into a broad field of research studying neuroimmune 
interactions in chronic pain. Microglia in the spinal cord are constantly surveying the 
environment to respond to endogenous signals indicating injury, and complement system 
recruitment is a key component to this response (Hong et al., 2016; Schafer et al., 2012; 
Vasek et al., 2016). There are currently a large number of preclinical, clinical trials, and 
existing therapies that target components of the complement system to treat a number of 
disorders (Ricklin & Lambris, 2016; Ricklin, Mastellos, Reis, & Lambris, 2017). The most 
widely used therapy is an antibody to C5, called eculizumab, used to treat the orphan 
disease atypical haemolytic uraemic syndrome, a deadly disease affecting kidney 
function. Clinical trials are underway targeting C3 and C3 convertase, which is responsible 
for the breakdown of C3 into C3a and C3b. These therapies are being developed for use 
in transplant patients, and lung disorders. Though microglia are considered a key 
component of the development and maintenance of neuropathic and inflammatory pain, 
the current therapies aimed at reducing microglial signaling are limited. The most widely 
used existing therapy for antagonizing microglia is minocycline, but a number of off-target 
effects and unwanted symptoms reduce the desirability of using minocycline to treat 
chronic pain (Haight, Forman, Cordonnier, James, & Tawfik, 2019). Specifically targeting 
complement activation, particular reducing signaling through C3aR1, remains a promising 
avenue to reduce microglial signaling while avoiding side effects and the vulnerabilities 
inherent in reducing widespread immune function.  
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Limitations 
 
The inspiration for this thesis was shaped by previous work from the Vulchanova lab on 
the neuropeptide precursor VGF, and the biologically active C-terminal peptides. Once the 
receptor for TLQP-21 was found to be C3aR1, it became possible to study this ligand and 
receptor interaction. Much of the previous work focused on reducing TLQP-21 signaling, 
and then measuring the behavioral effects (Fairbanks et al., 2014). The work presented in 
this thesis targeted the receptor’s involvement in neuropathic pain, but C3aR1 has another 
ligand, C3a, that is an important signaling factor in the complement cascade (Mathern & 
Heeger, 2015). C3a and its precursor C3 has been implicated in inflammatory and 
neuropathic pain (Jang et al., 2010; Levin et al., 2008). It is currently unknown what the 
relative contribution of TLQP-21 versus C3a are in any C3aR1 activation occurring 
following peripheral or central nervous system injury. Therefore it was impossible to 
decipher if there was a primary signaling mediator that was specifically affected by 
knocking down C3aR1, or if TLQP-21 and C3a were equally impacted.    
 
The biggest limitation of the experiments presented in this thesis was the variability of the 
spinal cord injuries. The complexity of the surgery and inconsistencies between injuries is 
a known issue in the spinal cord injury field. This variability is a double-edged sword. 
Having a heterogeneous population to study more closely recapitulates the individual 
variability present in the human population. This is important for assessment of broadly 
beneficial therapies. A drawback of this heterogeneity is that it can be difficult to parse the 
effects of various interventions. The importance of proper surgical training, in addition to 
having appropriate controls and an adequately powered experimental design is vital.  
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Another limitation that we encountered throughout our experiments was effectively 
reducing signaling through C3aR1. Our experiments in chapter one utilized the antagonist 
SB290157, which is known to have agonist activity in tissues with high expression of 
C3aR1 (Mathieu et al., 2005; Therien et al., 2014). It also antagonizes other unknown 
targets (Proctor et al., 2004). We encountered this issue in experiments not presented in 
this thesis, where the antagonist had activity in a global C3aR1 knockout mouse 
(unpublished work).  We aimed to explore reducing C3aR1 signaling without off-target 
effects by using a novel antisense oligonucleotide targeting C3aR1 for knockdown. 
Though the ASO completely knocked down C3aR1 expression in parenchymal microglia, 
the subarachnoid macrophages still exhibit expression. The functional relevance of this 
cell population in pain-related behavior is currently unknown. A floxed tdTomato-C3aR 
reporter knock-in mouse was developed, which has the potential of knocking down C3aR1 
expression depending on which Cre mouse line it is crossed with (Quell et al., 2017). Using 
a CX3CR1-CreER mouse, C3aR1 would be able to be deleted specifically from microglia 
and macrophages. This would be a potential way to examine complete knockdown of 
C3aR1 that can be turned on in an adult mouse to avoid compensatory mechanisms that 
take place during development.  
 
Future Directions 
 
Much of the work presented in this thesis has been examining how reducing signaling 
through C3aR1, primarily located on microglia, can influence the development of 
neuropathic pain. One area of research that still needs to be covered are the molecular 
consequences of microglial C3aR1 activation in this process. Activation of C3aR1 can 
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mediate apoptotic cell death, demyelination, and activation of resting microglia and 
astrocytes. What proinflammatory factors are released by microglia upon activation of 
C3aR1? Additionally, what are the consequences of this on neuronal activity? Microglia 
are capable of releasing ATP, proinflammatory cytokines and chemokines, and other 
pronociceptive products (Hawthorne & Popovich, 2011; Imura et al., 2013; H. Liu et al., 
2016). Our hypothesis is that activation of microglial C3aR1 leads to neuronal 
hyperexcitability, contributing to central sensitization and the generation of neuropathic 
pain. There are a few ways to probe this question, including stimulating microglial cultures 
with C3a and TLQP-21 and measuring cytokines released via ELISAs. This alone would 
be insufficient to answer the question though, as microglial cultures lack the complex 
cellular environment present in the dorsal horn. Calcium imaging and/or electrophysiology 
in spinal cord slices and in vivo in intact spinal cord is capable of probing the short-term 
consequences of microglial C3aR1 activation on neuronal activity. Preliminary work from 
the Vulchanova lab has found using in vivo electrophysiology recordings that bathing the 
exposed lumbar dorsal horn with TLQP-21 is capable of significantly increasing the 
number of wide dynamic range (WDR) neurons that responded to pinch over saline 
controls (unpublished). What would be interesting to examine is whether C3aR1 ASO 
knockdown of parenchymal microglia abolished this effect, or if this increase in WDR 
responses are primarily due to the subarachnoid macrophages that retain C3aR1 
expression even after treatment with C3aR1 ASO.  
 
Another area of research that can be explored following this thesis work is the function of 
C3aR1 expressing subarachnoid macrophages. There are very few studies examining 
non-parenchymal macrophages, searching for their function in the central nervous system. 
A recent study examined molecular signatures of these cells, which they dubbed border-
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associated macrophages, or BAMs (Van Hove et al., 2019). They found that non-
parenchymal macrophages are extremely heterogeneous, with tissue markers varying 
widely based on whether these macrophages were isolated from dura mater, choroid 
plexus, or subdural meninges. These diverse molecular signatures pointed toward 
specialization of these cells based on location, which potentially impacts their function. 
Those studies were examining BAMs of the brain, whereas our work found these C3aR1 
expressing macrophages surrounding the spinal cord. Future work can probe the 
molecular signatures of these cells to uncover their heterogeneity and gain insight into 
their potential function depending on what they express. Once more information is known 
regarding these cells, peripherally-restricted knockdown of specific subpopulations of cells 
can probe their involvement in pathological processes.  
 
Another future direction that can build upon the work presented in this thesis is to examine 
further the role of C3aR1 in damage following spinal cord injury. We found a potentially 
protective role of C3aR1 knockdown on the loss of light touch after SCI, specifically in 
mice with higher locomotor scores on day one. Work by James et al found a subset of still 
myelinated but functionally silent set of axons in the dorsal columns that were capable of 
being recruited to conduct action potentials when the lesion area was cooled. Future work 
could record from SCI mice and see if subjects that receive C3aR1 ASO exhibit increased 
conduction across the lesion than vehicle controls. Additionally, the spinal cords from SCI 
mice that received vehicle or C3aR1 ASO are going to be examined for differences in 
demyelinated regions and myelin breakdown products.   
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Overall, the work in this thesis highlights the potential relevance of C3aR1 as a therapeutic 
target following injury, and uncovers the complex role complement receptor-mediated 
immune signaling has in neuropathic pain. 
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